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Cover figure: Schematic figure showing “the cycle” of modern structural bi-
ology by photographs, “the cycle” includes some or all of the following in-
termediates: target selection and construct design <-> molecular biology for 
cloning of wild-type protein and protein mutations <-> protein expression 
for activity and functional studies <-> large-scale protein production and pu-
rification for structural biology <-> crystallization of protein <-> crystallo-
graphic data collection, phasing and refinement <-> new biological knowl-
edge analysed from the final structure and the start of a new cycle. 
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Abstract 
 
Veli-Pekka Jaakola (M.Sc., engineer) 2005. Biochemistry, Department of Biological 
and Environmental Sciences, Faculty of Biosciences, University of Helsinki 
D ssertationes bioscientiarum molecularium Universitatis Helsingienis in Viikki i
i .
.
 
G protein coupled receptors (GPCRs) comprise the largest integral membrane 
protein superfamily identified in Eukaryota. α2 adrenoceptors (α2-ARs) are proto-
typical GPCRs which initiate various physiological responses after activation by 
nor-epinephrine or epinephrine. Of the more than one thousand mammalian GPCRs 
identified so far, only the bovine rhodopsin crystal structure has been solved. This 
is mainly due difficulties in expressing, producing, purifying and crystallizing re-
combinant GPCRs. 
The primary aim of my thesis work was to develop a system capable of pro-
ducing GPCRs in quantities suitable for crystallographic studies. For this purpose, I 
studied expression of the α2-AR subtype B (α2b-AR) in the halophilic Archaeon 
Halobacter um salinarum. H  salinarum produces very high-levels of bacteri-
orhodopsin (bR), which is structurally analogous to the GPCRs. Functional, but un-
stable, α2b-AR expression was observed to be dependent on the downstream coding 
regions. For this reason, a second approach was selected: H  salinarum expression 
of extramembranous domains of GPCR in the bR skeleton. A large third intracellular 
loop (3i) of α2b-AR or parts of it were incorporated into bR. A fusion protein carry-
ing 89 residues from α2b-AR was expressed at very high levels, purified, character-
ized spectroscopically and crystallized. This approach is a new method to produce 
GPCR domains in quantities needed for biophysical studies. 
In addition, I noticed the unusually low net hydrophobicity and high net 
charge of extramembranous parts of α2-ARs and their orthologs. To analyze this 
further, various folding and unfolding prediction programs were applied to analyze 
human GPCRs and the results compared to those of membrane proteins of known 
structure (MPSs) and to intrinsically unstructured proteins (IUPs). Our results sug-
gest that human GPCR extramembranous domains include long disordered regions, 
unlike MPSs. The predicted disorder occurred primarily in the amino terminal, car-
boxyl terminal and 3i domain regions. 
Finally, it was decided to remove the IUP-like sequences from α2b-AR 3i, and 
to study the effects on ligand binding and G protein functionality in mammalian cells. 
Some of the 3i truncations caused minor changes in agonist binding properties, but 
not in antagonist binding. The truncated receptor constructs may be more stable 
upon purification and crystallization since they do not carry IUP-like regions, and 
thus be useful for structural characterization of α2b-AR. These results emphasize 
the importance of GPCR target selection for crystallographic studies and co-
crystallization with an appropriate interacting partner. Moreover, the IUP-like re-
gions in human GPCRs may have structural and functional consequences. 
 
Keywords: H. salinarum, membrane proteins, α2 adrenoceptors, G protein coupled 
receptors, over-expression, intrinsically unfolded proteins, radioligand binding, ge-
netic engineering, x-ray crystallography. 
Lyhennelmä (Synopsis in Finnish) 
 
Veli-Pekka Jaakola (fil.maist., ins.) 2005. Biokemia, Bio- ja ympäristötietei-
den laitos, Biotieteellinen tiedekunta, Helsingin yliopisto 
Dissertationes bioscientiarum molecularium Univers tatis Helsingienis in V ikki i i
 
 
Rakenne-aktiivisuus-suhteiden vuorovaikutustutkimuksia heptahelikaalisilla 
solukalvoproteiineilla 
 
olukalvoproteiinien geenit muodostavat n. 25 % ihmisen tunnettujen 
proteiinien geeneistä. Yhdistelmä-DNA-tekniikoiden avulla on pystytty 
mm. tuottamaan luontaisesti vähäisessä määrin esiintyviä proteiineja 
riittävän suuria määriä niiden kolmiulotteisen avaruusrakenteen ja toiminnal-
listen ominaisuuksien yksityiskohtaiseksi selvittämiseksi. Yli 30000 proteiinin 
avaruusrakenne on pystytty selvittämään pääasiassa joko röntgensädekristal-
lografian tai ydinmagneettisen resonanssi-spektroskopian avulla - näistä ai-
noastaan n. 200 on solukalvoproteiineja. 
S 
 
G-proteiinikytkennäisten reseptorien (GPCR) geeniperhe on määrillisesti 
suurin solukalvoproteiinien geeniperheistä. Lääkeaineista arviolta puolet vai-
kuttaa GPCR:en välityksellä. Adrenoseptorit (AR) l. adrenergiset reseptorit 
kuuluvat GPCR-perheeseen ja aktivoituvat sympaattisten postganglionaaris-
ten hermojen päissä ja soluissa adrenaliinin (epinefriini), noradrenaliinin (no-
repinefriini) ja muiden katekoliamiinien välittäminä. AR:t vaikuttavat useisiin 
elimistön elintärkeisiin toimintoihin, kuten esim. verenkiertojärjestelmään, 
hengitysteiden sileään lihakseen sekä hiilihydraatti- ja rasvahappoaineen-
vaihduntaan. Kliinisesti näihin reseptoreihin vaikuttavia lääkeaineita voidaan-
kin käyttää monien erilaisten elimistön toimintahäiriöiden hoidossa. GPCR:lle 
yhteisessä rakennemallissa reseptorin aminohappoketju muodostaa seitsemän 
solukalvon läpäisevää jaksoa (7-TM), joiden väliset jaksot ovat sytoplasmaan 
ja solun ulkopinnalle työntyviä silmukoita. Silmukkajaksojen pituus vaihtelee 
muutamasta aminohappotähteestä satoihin aminohappotähteisiin. 7-TM malli 
pohjautuu mm. naudan rodopsiinin röntgenkristallografiseen kiderakentee-
seen, joka on ainoana GPCR:na onnistuttu selvittämään. 
 
Suolameristä ja -järvistä eristetty Halobacterium salinarum on yksisoluinen 
arkkieliöihin (Archaea) lukeutuva mikro-organismi. Se tuottaa merkittävissä 
määrin bakteriorodopsiinia (bR), joka toimii protonipumppuna H. salinarum 
solukalvolla. Useita bakteriorodopsiinin ja sen protonipumpun toimintaan liit-
tyviä kiderakenteita on selvitty. Rakenteet ovat samankaltaisia GPCR:lle tyy-
pillisen 7-TM mallin kanssa. H. salinarum – bR tuotto- ja eritysmekanismia 
voidaan mahdollisesti käyttää isäntäsoluna aitotumallisten GPCR:n tuottami-
seen rakennebiologiseen ja -fysikaaliseen tutkimukseen tarvittavassa määrin. 
 
Väitöskirjatyössä pyrittiin selvittämään α -adrenoseptorin (2b α2b-AR) ja sen 
osien kiderakenteita röntgenkristallografian avulla ja tutkimaan reseptorin 
toimintaa geneettisten, farmakologisten ja solubiologisten menetelmien avul-
la. 
 
Ensimmäisessä osatyössä α2b-AR solunkalvon läpäisevien alueiden tuottoa 
tutkittiin H. salinarum isännässä geneettisillä reseptorivariaatioilla. Useiden 
reseptorivariaatioiden lähetti-RNA tasot vastasivat lähes luontaisen bR:n 
vastaavia. Proteiinin ilmentyminen oli tästä huolimatta sekä epästabiilia että 
vähäistä. Toisessa osatyössä α2b-AR:n kolmas solunsisäinen (3i) silmukkajak-
so liitettiin geneettisesti bR:n vastaavalle paikalle. Alue muodostaa toiminnal-
lisen jakson (yli 150 aminohappotähdettä), mutta ko. aluetta ei ole kyetty ai-
kaisemmin tuottamaan funktionaalisiin kokeisiin in vivo. Parhaiten ilmenty-
nyttä bR-α2-AR 3i fuusiota tuotettiin n. 30 % luontaisen bR:n tasoista. Spekt-
roskoopisen analyysin perusteella bR-α2-AR 3i fuusio ei merkittävästi vaiku-
ta bR:n protonipumpun toimintaa. Fuusio kuitenkin muuttaa protonipumpun si-
säistä kinetiikkaa, mikä mahdollisesti osoittaa, että 3i jakso osallistuu vuoro-
vaikutuksiin, jotka vaikuttavat solunsisältä solunulkopuolelle. Mutanttiresep-
tori myös kiteytettiin, mutta saadut proteiinikiteet osoittautuivat liian epäjär-
jestyneeksi röntgenkristallografiseen analyysiin. Mahdollisesti joko kiteytys-
olosuhteita parantamalla tai yhteiskiteytyksellä G-proteiinien/muiden sääte-
lyproteiinien kanssa kiderakenne pystytään selvittämään. Osajulkaisun tulok-
set esittävät uuden tavan tuottaa funktionaalisesti tärkeää reseptoridomeenia 
riittävässä määrin biofysikaalisiin mittauksiin riittävinä määrinä. 
 
Työn kuluessa havaittiin, että GPCR:en solukalvon ulkopuolisilla aminohap-
posekvenssillä on epätavallisen alhainen vettähylkivyys (hydrofobisuus) ja 
korkea kokonaisvaraus. Nämä ominaisuudet ovat tyypillisiä proteiineille, joilla 
ei ole todettu säännöllistä kolmiulotteista rakennetta fysiologisissa olosuh-
teissa. Rakenteettomat proteiinit osallistuvat useisiin tärkeisiin solua säätele-
viin perusprosesseihin, kuten esim. solunjakautumiseen, DNA:n kopioimi-
seen/korjaamiseen ja solujenväliseen viestintään. Tyypillisesti näiden proses-
sien aikana rakenteettomat proteiinit ovat vuorovaikutuksessa muiden prote-
iinien kanssa joiden avulla niille muodostuu säännöllinen kolmiuloitteinen ava-
ruusrakenne. Työssä verrattiin GPCR:en (n=343), tunnettujen solunkalvopro-
teiinien (n=91), rakenteellisten proteiinien (n=275) ja rakenteettomien prote-
iinien (n=91) aminohapposekvenssejä algoritmeilla, joiden avulla voidaan en-
nustaa proteiinin laskostumista ja mahdollista epäjärjestyneisyyttä. Tulosten 
perusteella GPCR:n amino- ja karboksyyliterminaalinen jakso sekä kolmas 
solunsisäinen jakso sisältävät pitkiä epäjärjestyneitä alueita. Vastaavia alueita 
ei löydy rakenteista, jotka on talletettu rakennetietokantaan. Edellä mainittu-
jen alueiden kokonaishydrofobisuus ja -varaus ovat tyypillisiä rakenteetto-
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mille proteiineille, mutta jaksojen aminohappojakauma poikkeaa rakenteetto-
mista proteiineista. 
 
α2b-adrenoseptorin kolmannen solunsisäisen jakson (α2b-AR 3i) merkitystä 
välittäjäaineen sitoutumisessa ja G-proteiiniaktivaatiossa selvitettiin poista-
malla α2b-AR 3i:n alueita geneettisesti ja ilmentämällä mutatoituja reseptorei-
ta viljellyissä kiinanhamsterinsoluissa. Ligandinsitoutumis- ja G-
proteiiniaktivaatiokokeiden perusteella α2b-AR 3i solukalvoa lähellä olevat 
amino- ja karboksyyliterminaaliset alueet osallistuvat G-
proteiiniaktivaatioon. Jakson deleetiot eivät aiheuttaneet muutoksia tutkittujen 
antagonistien sitoutumisvoimakkuuteen. Jakson deleetiot vaikuttivat kuitenkin 
tutkittujen agonistien sitoutumisvoimakkuuksiin. 
 
Tämän työn tulosten perusteella on mahdollista paremmin valita GPCR:ta ra-
kennebiologisiin ja muihin biofysikaalisiin tutkimuksiin. H. salinarum on uusi 
tuottoisäntä GPCR-jaksojen tuottamiseksi biokemiallisiin ja –fysikaalisiin tut-
kimuksiin niiden natiivissa laskostumis- ja solukalvoympäristössä. Työssä 
havaitulla mahdollisella GPCR:en rakenne-epäsäännöllisyydellä voi olla mer-
kittävä rooli erilaisten G-proteiinien ja muiden säätelijäproteiinien sitoutumi-
sessa ja säätelyssä välittäjäaineen aktivoimaan GPCR:iin. 
 
Asiasanat: H. salinarum, solunkalvon läpäisevät proteiinit, α2 adrenoseptorit, 
G-proteiinikytkennäiset reseptorit, proteiinin tuotto, epäjärjestyneet proteii-
nit, radioligandin sitoutuminen, yhdistelmä-DNA-tekniikka, röntgensädekris-
tallografia. 
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1. 
 
Introduction 
 
ntegral transmembrane proteins represent more than a quarter of the 
proteins encoded in the human genome, but still less than one percent 
(less than 200 structures) of the proteins of known structure (more than 
30,000 structures). Heptahelical transmembrane proteins (7-TMs) and G 
protein coupled receptors (GPCRs) form the largest, most ubiquitous and 
most versatile superfamily of integral transmembrane proteins. They are re-
ceptors which initiate cellular responses to extracellular signals by activating 
membrane-associated guanine nucleotide binding regulatory proteins or G 
proteins. Consequently, GPCR natural and synthetic ligands – hormones, 
neuro-transmitters, ions, chemokines, odorants, glycoproteins - are impor-
tant therapeutically; nearly 50% of currently used drugs have an effect on 
GPCRs [1]. 
I 
 
Near atomic resolution structures are essential to understand ligand-GPCR-
G protein signalling transduction and intracellular communications in detail. 
Crystal structures of individual GPCRs would allow rational design of drugs 
to treat human diseases. However, each step, including over-expression, 
production, purification, crystallization and refinement (see cover figure), in 
the cycle to solve the crystal structure of a GPCR can be a difficult, demand-
ing and time-consuming task. Of the five steps mentioned above, production 
and crystal growth are proving the most challenging. Indeed, despite huge 
efforts, the only GPCR crystal structure solved to date is the inactive inter-
mediate form of bovine rhodopsin [2-4]. The material for the crystallization 
was obtained by native expression in bovine retina. 
 
The halophilic Archaeon Halobacterium salinarum is a harmless and non-
toxic microorganism. Halophiles grow in marine salterns and hypersaline 
lakes, such as the Dead Sea and the Great Salt Lake, where the salinity is 
more than ten times that of normal seawater. H. salinarum produces large 
quantities of the heptahelical transmembrane protein bacteriorhodopsin. The 
crystal structures of recombinant wild-type bacteriorhodopsin (bR) and sev-
eral intermediates have been solved at near atomic resolution. The H. salina-
rum – bacteriorhodopsin recombinant host system could be used for the pro-
duction of eukaryotic GPCRs. 
 
The present thesis work describes a series of studies intended ultimately to 
solve the structure of human α2b adrenoceptor (α2b-AR), a prototypical mem-
ber of GPCRs, utilizing the H. salinarum – bacteriorhodopsin production sys-
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tem. Several approaches for expression of α2b-AR or a part of α2b-AR in H. 
salinarum were explored (Studies I and II). Bacteriorhodopsin–α2b adrenocep-
tor third intracellular domain fusions were constructed (bR-α2b-AR 3i), from 
which large-scale production and purification were achieved (Study II). Dur-
ing the course of research for studies I and II, I noticed that α2b-AR extra-
membranous regions had unusual sequence properties. They have both a 
very high net charge and unusual net hydrophobicity properties; both prop-
erties are preserved during evolution - even when the amino acid sequence 
homology is totally lost. These observations led us to study this further as 
these properties are common for intrinsically unfolded/unstructured proteins 
(IUPs) and protein domains (also called naturally unfolded proteins). 
 
We selected a representative set of human GPCR sequences and compared 
them to the membrane proteins of known three-dimensional structure and to 
intrinsically unfolded proteins using unfolding prediction programs. Based on 
our analysis, human GPCRs include many long regions (more than 30 resi-
dues) with predicted disorder, while MPSs – particularly heptahelical trans-
membrane proteins (7-TMs) – do not have such regions (Study III). 
 
Recombinant mammalian cell lines expressing various α2b-AR 3i truncations 
were constructed and used to characterize the role of 3i in ligand binding and 
G protein coupling (Study IV). Finally, several bacteriorhodopsin mutants and 
bR-α2b-AR 3i were crystallized in detergent lipid bilayer gels (also called in 
cubo, lipid cubic phases (LCP) and bicelle-lipid-detergent (BLC) methodolo-
gies) and two recombinant bacteriorhodopsins were solved at near atomic 
resolution (manuscript in preparation). 
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2.1.1. Concept of G protein coupled receptors 
2.1. G protein coupled receptors and adrenoceptors 
Literature review 
 
2. 
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n this review, I will start with a brief description of G protein coupled re-
ceptors focusing, in particular, on functional and structural related studies 
of adrenoceptors. I then will summarize the recent literature on recombi-
nant production host systems for G protein coupled receptors, especially re-
combinant expression of adrenoceptors. Finally, I will discuss the role of   
intrinsic structural disorder in proteins and protein domains. 
I 
Based on amino acid sequence similarity, the GPCRs can be classified into 
three to six main subfamilies (Table 2.1.1.1; www.gpcr.org/7tm/ [5]). Class 
A (also called the rhodopsin-like receptor family) is the largest and most ex-
tensively studied. It is characterized by the presence of twenty conserved 
residues in the TMs. Class B (the secretin/glucagon receptor family) has a 
large N terminal domain that contains six highly-conserved Cys residues in 
addition to the twenty conserved residues found in the TMs. Class C (the 
metabotropic neurotransmitter and Ca2+ sensing receptor family) is charac-
terized by a very long N-terminal domain that contains nearly twenty con-
served Cys residues in addition to those conserved residues localized in the 
TMs. Class D includes yeast pheromone receptors. Class E comprises the 
frizzled/smoothened receptors of fly embryonic development. 
 
The G protein coupled receptors members share a common structural motif 
of seven transmembrane helices (7-TMs), connected by three intracellular 
loops (1i-3i), three extracellular loops (1e-3e), with an extracellular amino 
terminal end (N) and an intracellular carboxyl terminal end (C) (Figure 
2.1.1.1). This basic motif has recently been verified by x-ray crystallography 
on bovine rhodopsin [2-4]. Functionally, GPCRs are responsible for the 
communication events from the extracellular environment to the cell by acti-
vating heterotrimeric G proteins. For this, the extracellular and TMs regions 
are involved in ligand binding whereas the intracellular regions are involved 
in signalling (Figure 2.1.1.1). 
 
 
 
Figure 2.1.1.1: Schematic diagram of the structure of bovine rhodopsin, a prototypical GPCR (adapted from [4], prepared 
using Pymol [6]; PDB-code: 1F88). The structure is viewed from the outside of the cell (A), parallel to the membrane (B) 
and from the inside of the cell (C). The structure has six key features: 1. seven transmembrane α helixes; 2. three external 
loops (1e-3e); 3. three cytosolic loops (1i-3i); 4. a β-hairpin loop IV-V between the helices; 5. a ligand binding pocket in 
the middle of the TMs; and 6. cytosolic helix VIII. The rainbow colour coding starts at the amino terminus (N) in blue and 
ends at the carboxyl terminus (C) in red. The retinal ligand is shown as a purple stick model. 
 
 
 
Finally, there is also an additional GPCR family, the cyclic adenosine mono-
phosphate receptors (cAMPr) that have been found in the slime mold Dic-
tyostelium discoideum. 
 
Table 2.1.1.1: Classification and subfamilies of GPCRs. 
Table is adapted from [5]. 
 
GPCRs versus bacteriorhodopsin. H. salinarum can produce the heptahelical 
transmembrane protein bacteriorhodopsin (bR) at up to 25 nmol/mg (above 
70% of its entire membrane). bR converts light energy absorbed by the 
chromophore retinal to a transmembrane proton gradient that can be used by 
the cell to perform energy-requiring processes. The retinal is linked via a 
Schiff base to Lys216, located near the middle of TMVII. The proton transport 
cycle or photocycle involves photoisomerization of the retinal from all-trans-
retinal to 13-cis-retinal followed by a linear series of intermediate confor-
mations, or states, with distinct visible absorbance properties: Gground state -> 
K <-> L <-> M <-> N <–> O -> Gground state all of which have been well char-
acterized by spectroscopy [7]. Moreover, the ground state and several in-
termediates have been solved by cryo-EM and x-ray crystallography [7,8]. 
These structures define the molecular mechanism of proton pumping at high 
resolution. Although, bR and bovine rhodopsin have the same overall topo-
logy, structural pairwise comparisons of helices show differences, especially 
between TMIV and TMV [9]. Also, the various kinks/twists in the bovine 
rhodopsin’s TMs form differences between these two structures. These dif-
ferences are large enough to influence homology modeling efforts for other 
GPCRs which are based on the bR ground state structure [9]. 
Classifica-
tion 
(Subfamily 
name) 
Class A 
(Family 1 
or A) 
Class B 
(Family 2 
or B) 
Class C 
(Family 3 
or C) 
Class D 
(Family 4 
or D) 
Class E 
(Family 5 
or E) 
cAMPrs 
of D. dis-
coideum 
No of 
members 
>700 >25 >10 Few Few Few 
Includes Opsins, 
Odorants, 
Mono-
amines, 
Purines, 
Opiates, 
Chemoki-
nes, 
Peptide 
and glyco-
protein 
hormones 
Parathy-
roid hor-
mone, 
Parathy-
roid-
related 
hormone, 
Calcitonin 
Metabo-
tropic glu-
tamate 
hormone, 
extracellu-
lar Ca2+ 
sensing 
receptor, 
Putative 
taste and 
pheromone 
Yeast α-
factor    
receptor, 
Yeast a-
factor    
receptor 
 
Frizzled 
and 
smooth-
ened    
receptors 
Cyclic 
adenosine 
mono-
phosphate 
receptors 
 
2.1.2. Concept of heterotrimeric G proteins 
 
The interaction of GPCR with its proper heterotrimeric G protein is the first 
molecular step in signal transduction that regulates cellular functions [10]. 
The G protein consists of three subunits, α, β and γ. There appear to be more 
than twenty different α subunits (including splice variants), five β subunits 
and fourteen γ subunits [11]. The α (catalytic) subunit is responsible for 
guanosine triphosphate (GTP) and guanosine diphosphate (GDP) binding and 
for hydrolysis of GTP, while the β and γ subunits form a tightly bound βγ het-
erodimer complex. α and βγ subunits are found in vivo in several possible 
combinations. Both the α subunit and βγ heterodimer are responsible for sig-
nal transduction. The effector proteins interacting with different α subunits 
are better known than those that interact with the βγ heterocomplex (Table 
2.1.2.1). Also, the different combinations of βγ dimers have not been exten-
sively studied, and such variety might further increase the diversity of re-
ceptor-G protein specificity. 
 
For clarity, G proteins are usually described by the α subunits; for instance 
the Gi heterotrimeric complex contains Gαi and Gs contains Gαs. α subunits 
can be classified into four main categories (Table 2.1.2.1): Gs proteins stimu-
late adenyl cyclase; Gi proteins inhibite adenyl cyclase and activate G protein 
coupled inwardly rectifying potassium channels; Gq proteins activate phos-
pholipase Cβ; and G12 proteins activate Rho guanine-nucleotide exchange 
factors. 
 
A second classification of G proteins can be made based on their sensitivity 
to Vibrio cholerae toxin (CTX) or Bordetella pertussis toxin (PTX) (Table 
2.1.2.1). CTX prevents the hydrolysis of Gαs GTP to its GDP bound state and, 
as a result, the G protein remains in the active state. PTX prevents the re-
lease of bound GDP, locking Gα in the inactive state. 
 
Structures of all the subunits have been solved by x-ray crystallography in 
various activation states and in complexes with various effector and regula-
tory proteins [12-16]. The α subunit is structurally homologous to other 
members of the guanine nucleotide binding protein superfamily. The β sub-
unit forms a β-propeller consisting of toroidal arrangement of β sheet and the 
α-helical γ subunit is usually found as a complex with the β unit (Figure 
2.1.2.1). 
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Table 2.1.2.1: Classification and functions of G protein subunits. 
Subunit Toxin sensitiv-
ity 
i
 
lTissue distr bu-
tion
Effector coup ing 
Gαi    
i1 PTX Wide AC (I, V, VI) -; CaL, 
CaN  -; Kir, KATP) +; 
PLC +;  
i2 PTX Wide “ 
i3 PTX Wide “ 
oA PTX Brain AC -; K+ +; PLC+; 
Ca2+ CaL, CaN - 
oB PTX Brain “ 
t1 PTX/CTX Retina; taste 
cells 
cGMP phosphodi-
esterase + 
t2 PTX/CTX Retina; taste 
cells 
cGMP phosphodi-
esterase + 
gust PTX/CTX? Taste cells cAMP phosphodi-
esterase + 
z  Brain AC - 
Gαs    
s CTX Wide AC +; Kca +; CaL + 
olf CTX Brain/olfactory AC + 
Gαq    
15  Myeloid PLCβ + 
16  Myeloid “ 
14  Stromal/epithelial “ 
11  Wide “ 
q  Wide “ 
Gα12   “ 
12  Wide Na+/H+ antiporter 
activity + 
13  Wide  
Gβ   # 
β-β5  Wide  
Gγ   # 
γ1  Retina  
γ2, γ3  Brain  
γ4-γ14  Wide  
+, increase activity of effector; -, decrease activity of effector; AC, adenylyl 
cyclases; cAMP, cyclic adenosine monophosphate; CaL, L-type calcium 
channel; CaN, N-type calcium channel; cGMP, cyclic guanoside monophos-
phate; CTX, Vibrio cholerae toxin; KATP, ATP-inhibited potassium channel; 
Kca, calcium-activated potassium channel; Kir, inwardly rectifying potassium 
channel; PDE, phosphodiesterase; PLC, phospholipase C; PTX, Bordetella 
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pertussis toxin; Gα subfamilies: s, stimulatory; i, inhibitory; o, other; t, trans-
ducin; olf; olfactory; gust; gustducin; other abbreviations (z, q, 11, 12, 13, 14, 
15 and 16) describe gene products that initially had no functions assigned to 
them. #Gβγ complex are known to interact with various effectors such as 
phosphatidylinositol 3-kinase, K+ channels, ACs, phospholipases and β-AR 
kinases. The table is adapted from [10,17,18]. 
 
 
 
Figure 2.1.2.1: Schematic view of a GPCR and GPCR signalling components. A 
diversity of signalling molecules can stimulate the heptahelical GPCR, which 
is located in the plasma membrane. The GPCR controls the activity of effec-
tors, which typically are enzymes and ion channels, by catalysing GDP-GTP 
exchange on the heterotrimeric G proteins. PLC, phospholipase C; PKA, 
adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase. Inset: 
schematic diagram of the structure of heterotrimeric G protein (adapted from 
[12-16]). 
 
2.1.3. GPCR signalling cycle and desensitization 
 
G proteins bind to and are activated by ligand-bound GPCRs (Figures 2.1.3.1 
and 2.1.3.2). These ligands include photons, odorants, neurotransmitters, 
glycoproteins, hormones, ions and chemokines. There are various mathe-
matical models to describe activation of GPCRs. The most widely used 
model, the extended ternary complex, ETC, and its extension the cubic ter-
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nary complex, CTC, (Figure 2.1.3.1; for a review, see [19]), assume that, in 
the absence of a ligand, there is an equilibrium between two functionally and 
structurally different states: the inactive (low affinity) (R) and the active 
(high affinity) (R*). The ability of ligands to induce physiological responses - 
the efficacy of the ligand - varies: a full agonist binds and stabilizes the ac-
tive state (R*), which has high coupling efficiency for a specific G protein 
(R*G). A partial agonist binds and stabilizes the active state less efficiently, 
and causes only a partial G protein activation. A neutral antagonist recog-
nises all receptor forms equivalently and has no effect on the equilibrium be-
tween (R) and (R*) states. An inverse agonist binds and stabilizes the inactive 
state (R), thus decreasing the basal, agonist independent, G protein activity. 
The ETC model can describe these different events. The CTC model includes 
the possibility that the inactive receptor forms (R and AR) interact with G 
protein, which is not allowed in the ETC model (Figure 2.1.3.1). The various 
binding models do not, however, describe the molecular basis of ligand bind-
ing and G protein activation, because of the lack of empirical GPCR:ligand:G 
protein complex structures. 
 
Nevertheless, biochemical and biophysical studies with various members 
from GPCR family A indicate that the transition from the inactive (R) to the 
active (R*) state involves rotation and tilting of transmembrane helices rela-
tive to each other [20-22]. A short time ago, a sequential binding model was 
described for β2−AR [23]. In this model, agonist binding results in receptor 
activation through a series of discrete intermediate conformational states (R 
+ A <-> AR1 <-> ARn <-> AR*). 
 
 - 24 -
A 
 
 
 
B 
 
 
 
Figure 2.1.3.1: The extended ternary complex, ETC, and cubic ternary com-
plex, CTC, models for GPCRs. In the ETC (A), the equilibrium between the 
inactive (R) and active (R*) forms is described by the allosteric constant (L). 
G proteins (G) bind to partially activated or fully activated receptor forms. 
This can happen either via ligand (A) binding (AR*G) or spontaneously (R*G), 
and in the G protein-coupled states produce physiological responses. In the 
CTC (B), both inactive and active receptor forms can interact with G pro-
teins. The allosteric constant is defined as (L=[R*]/[R]). The receptor has an 
affinity association constant Ka for the ligand and Kg for the G proteins. α, β 
and γ are modifier factors of affinity when the receptor is in the active, G 
protein bound or ligand bound forms, respectively. The σ factor is the com-
bined effect of any two of ligand binding, activation, or G protein activation 
parameters. 
 
In the resting/basal state of the G protein signalling cycle, the βγ complex 
and the GDP bound α subunit are associated (Figure 2.1.3.2). In this state, 
the G protein can be recognized by an appropriate activated GPCR, which in-
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teracts with the heterotrimeric G protein. The GPCR:G protein interaction 
results in the exchange of GDP for GTP in the α subunit. GTP binding to the 
α subunit induces a conformational change, which causes dissociation of the 
α subunit and the βγ complex from each other and from the GPCR. The GTP-
bound α subunit as well as the βγ dimer are now able to interact with effector 
proteins. The slow inherent GTPase activity in the α subunit terminates the G 
protein signalling. The resultant α:GDP complex is inactive, and, by reasso-
ciating with the βγ heterodimer complex, it inactivates the βγ complex (Figure 
2.1.3.2). Some GPCRs, however, undergo spontaneous activation in the ab-
sence of agonist [24]. 
 
 
 
Figure 2.1.3.2: The G protein cycle. In the absence of agonist (A), GPCRs are 
mainly in the low affinity state (R). After agonist binding, the receptor is acti-
vated in the high affinity state (R*), and the agonist-GPCR-G protein com-
plex is formed. GTP replaces GDP in Gα. After that the G protein dissociates 
into the Gα subunit and the Gβγ heterodimer, which then activate several ef-
fector proteins. The built-in GTPase activity of the Gα subunit cleaves the 
terminal phosphate group of GTP, and the GDP bound Gα subunit reassoci-
ates with Gβγ heterodimer. This results in the deactivation of both Gα and 
Gβγ. The G protein cycle returns to the basal state. RGS, regulator of G pro-
tein signalling. 
 
 - 26 -
G protein signalling is not a constant process; high activation of GPCR re-
duces the ability to be stimulated in the future (desensitization), whereas low 
activation increases the ability (sensitization). Agonist induced desensitiza-
tion has been classified into agonist-specific (homologous) or agonist-non-
specific (heterologous) desensitization. After agonist binding, primary desen-
sitization is controlled by receptor phosphorylation. This occurs via second-
messager kinases or by a distinct family of GPCR kinases (for reviews, see 
[25,26]). Second-messenger kinases, such as protein kinase A (PKA) and 
protein kinase C (PKC), directly uncouple GPCRs from their G proteins. Sec-
ond-messager kinases can also mediate agonist-non-specific desensitization 
where kinase activation by one type of GPCR causes phosporylation of an-
other GPCR. The second general mechanism for regulating GPCRs works via 
the G protein coupled receptor kinases (GRKs):β–arrestin mediated system 
[27,28]. In this, the agonist-occupied or actived GPCR is phosphorylated by 
GPRs. GPR phosphorylation causes binding of β-arrestin to the GPCR, which 
inhibits binding between GPCR and the G protein. The vast complexity of 
GPCR signalling has recently been further underlined by results suggesting 
that GPCRs may not exclusively work via heterotrimeric G proteins [29,30]. 
 
There is continuous movement of receptors between the plasma membrane 
and endosomal vesicles, and between synthesis in the endoplastic reticulum 
via Golgi apparatus and lysosomal degradation (Figure 2.1.3.3). Agonist acti-
vation of the receptor usually causes the removal of receptors from the 
plasma membrane to clathrin coated vesicle pits by a process called inter-
nalization. After this, internalized receptors are either recycled to the plasma 
membrane (resensitization) or targeted for degradation in lysosomes (down-
regulation). Constant stimulus causes receptor loss from the plasma mem-
brane. There are several different internalization pathways reported [28], in 
addition to internalization via clathrin, some of which work via caveolae or 
uncoated vesicles. 
 
Several recent studies suggest that GPCRs can exist as dimers or as part of 
larger oligomeric complexes [31]. Although GPCR dimerization is not essen-
tial for GPCR function, it might contribute to the diversity of signalling in vivo 
by directly altering ligand binding, desensitization or compartmentalization. 
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Figure 2.1.3.3: Typical cellular trafficking of GPCRs. After receptor activa-
tion, free Gβγ dimers recruit G protein-receptor kinases to the GPCR, where 
they specifically phosphorylate agonist occupied GPCRs. This leads to the 
recruitment of β-arrestin to the GPCR and targets the GPCR:β-arrestin com-
plexes to clathrin-coated pits. The GPCR is internalized into late endosomes 
and then either dephosphorylated and re-cycled to the plasma-membrane 
surface or degraded via the lysosomal degradation pathway. GRK, G protein 
coupled receptor kinase. 
 
2.1.4. Classification and functions of α2 adrenoceptors 
 
Adrenoceptors (ARs), also called adrenergic receptors or adrenoreceptors, 
are members of the GPCR family A (Table 2.1.1). ARs are located in neuronal 
and non-neuronal tissues throughout the body. ARs mediate different re-
sponses to the two natural catecholamines, epinephrine (adrenaline) and nor-
epinephrine (nor-adrenaline) and their synthetic analogues (Figure 2.1.4.1). 
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Figure 2.1.4.1: Schematic presentation of adrenoceptors, their Gα protein in-
teractions and secondary signalling partners. Activated α1-ARs interact pri-
mary with Gq which leads to an increase in phospholipase C, D and A2 activ-
ity. Activated α2-ARs interact primarily with Gi which leads to decrease of 
adenylyl cyclase activity and an increase in K+ channel activity; interactions 
with Go decrease Ca+ channel L and N type activity; β-AR couples primarily 
with Gs which leads to the increase of adenylyl cyclase and Ca2+ channel L-
type activity. AC, adenylyl cyclases; Ca2+, calcium channels in the ER; cAMP, 
cyclic adenosine monophosphate; DAG, diacylglycerol; IP3, inositol triphos-
phate; K+, potassium channel; PIP2, phosphatidylinositol bisphosphate; PKA, 
adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase; PLC, 
phospholipase C; +, increasing activity; -, decreasing activity; PKC protein 
kinase C. A ligand is indicated as polygon.  
 
The idea that there are receptors, or as then called “receptive substances”, 
was discovered by John Langley and Paul Ehrlich more than a hundred years 
ago (for a historical point of view, see [32]). At the beginning of the last 
century, Henry Dale observed that epinephrine constricted some blood ves-
sels while relaxing others [33]. After this, Raymond P. Ahlquist demon-
strated in 1948 that ARs can be divided into two distinct categories: α− and 
β-ARs, based on responses to different adrenergic receptor agonists, such as 
nor-epinephrine, epinephrine, and isoproterenol [34]. In 1967, Alonzo Lands 
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and co-workers [35] showed that β-ARs could be subdivided into two cate-
gories. Further studies with both pharmacological and molecular cloning 
techniques have now shown the existence of two main α-AR subtypes, sub-
divided into α1a-AR, α1b-AR, α1d-AR, α2a-AR, α2b-AR, α2c-AR and α2d-AR, 
respectively, and three β-AR subtypes, β1-AR, β2-AR and β3-AR. 
 
The characterization of α2-AR into three distinct subtypes, α2a–AR/(α2d–AR), 
α2b–AR and α2c–AR, is based on radioligand binding profiles, amino acid se-
quences and chromosomal locations [36-39]. The human orthologs are oc-
casionally called α2-C10, α2-C2 and α2-C4, respectively, to indicate their 
chromosomal location. Although α2d–AR has a distinctive pharmacological 
profile, it is actually a species variation of α2a-AR: the difference between 
the 2a and 2d forms is a single point mutation (Cys201Ser), which causes 
lower affinity for some α2–AR antagonists [40]. α2d-AR is found in some   
rodents, ruminants and fish, but not in pigs and humans. 
 
2.1.5. α2-AR G protein signal-transduction mechanism 
 
α2-ARs share sequence homology only in the TMs and they have sufficient 
structural heterogeneity in extramembranous domains that serve for their 
differential interactions with various G proteins (Figure 2.1.3.1 and Figure 
2.1.4.1). An activated α2-AR can simultaneously activate several signal-
transduction systems, thus causing various physiological responses. Gene-
rally, activation of α2-ARs causes inhibition of AC and voltage-gated Ca2+ 
channels or activation of receptor-linked K+ channels via Gi/Go [41]. Other 
signalling-transduction pathways, such as phospholipases A2, C and D, and 
mitogen-activated protein kinase have also been characterized. All three 
subtypes have been shown to couple functionally to both Gi (inhibitory) and 
Gs (stimulatory) proteins in membranes from CHO cells. 
 
2.1.6. Cellular and subcellular location of α2-ARs 
 
α2-ARs are found in central and peripheral nervous systems (CNS and PNS), 
but also in non-neuronal tissues (Table 2.1.6.1). In neurons, both pre- and 
postsynaptic localization has been characterized. Based on in situ mRNA hy-
bridization, immunohistochemistry, radioligand binding, receptor autoradio-
graphy and other related methodologies, α2-ARs have individual anatomical 
distributions in CNS, PNS and peripheral organs [42]. α2a/d-AR is present 
widely in both neuronal tissues and in peripheral organs, while α2c-AR is 
present mainly in neuronal tissues.  α2b-AR is mainly present in peripheral 
tissues; it has been found only in a few neuronal cell types [43]. This kind of 
distribution suggests that the functional role of the three subtypes is differ-
ent (Table 2.1.7.1). 
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2.1.7. Functions of α2-ARs 
 
α2-ARs mediate a variety of functions in CNS, PNS and peripheral tissues 
(Table 2.1.7.1). Presynaptically located α2-ARs mediate the main function of 
α2-ARs: inhibition of nor-epinephrine and other neurotransmitter release 
from adrenergic nerves. α2-ARs located in the CNS have a role in regulation 
of blood pressure, hypothermia, pupil control and central cardiovascular re-
sponse. α2-ARs located in the peripheral nervous system have a function in 
vascular smooth muscle contraction, lipid hydrolysis inhibition, and hyperpo-
larization of sympathetic ganglia. In the peripheral tissues they increase 
muscle contraction in the heart and stimulate glycogen phosphorylation in the 
liver. 
 
Table 2.1.7.1: Overview of α2-ARs mediated physiological responses. 
Physiological responses  
α2a-AR α2b-AR α2c-AR 
Analgesia [44] 
Anaesthetic-sparing 
effect [44,45] 
Bradycardia and hy-
potension [46] 
Mediating hypothermia 
[44] 
Regulates presynaptic 
inhibition of neuro-
transmitter release 
[47,48] 
Regulates dopaminer-
gic and serotonergic 
systems [49] 
Sedation [44,45,49] 
Vascular relaxation 
[50] 
Vasoconstriction in 
some vasculature [46] 
Possible role in de-
velopmental or repro-
ductive processes 
[47] 
Mediates antinocep-
tive effect of N2O and 
possible other antino-
ceptive responses in 
the spinal cord 
[51,52] 
Salt-induced hyper-
tension [53] 
Vasoconstrictor re-
sponse to α2-AR ago-
nist [48,54] 
Possible minor role in 
mediating hypo-
thermia [49] 
Possibly regulates 
dopaminergic systems 
in the brain [48,49] 
Possibly modulates 
motor behaviour [55] 
Possibly mediates  
aggressive behaviour, 
startle reflex and its 
prepulse inhibition 
[56] 
Regulates presynaptic 
inhibition of neuro-
transmitter release 
[47] 
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α2-AR drugs. It is obvious from the fundamental physiological functions of 
α2-ARs (Table 2.1.7.1) that α2-ARs agonists and antagonists could have 
therapeutic utility. Various α2-ARs agonists and antagonists are used as 
drugs in humans and animals (Table 2.1.7.2), but the currently available 
drugs are not selective enough. 
 
Table 2.1.7.2: Examples of α2-ARs agonists and antagonists that are used as 
drugs. 
Drug  Use
Agonists  
α-methyldopa Hypertension 
Brimonidine Ocular hypertension/glaucoma 
Clonidine Hypertension/neurophatic pain 
Detomidine Animal anaesthesia 
Dexmedetomidine Anesthesia 
Guanabentz Withdrawal syndromes/analgesics 
Guanfacine Withdrawal syndromes/analgesics 
Medetomidine Animal anaesthesia 
Metaraminol Cardiogenic shock/hypotension 
Moxonidine Hypertension 
Nor-epinephrine/Epinephrine Cardiac arrest/hypotension 
Oxymetazoline Nasal decongestants 
Para-aminoclonidine Glaucoma 
Phenylephrine Hypotension/nasal decongestants 
Rilmenidine Hypertension 
Tizanidine Muscle relaxant/spasticity from stroke, 
cerebral trauma/multiple sclerosis 
UK-14,304 Glaucoma 
Xylometazoline Nasal decongestants 
Xylazine Animal anaesthesia 
Antagonists  
Atipamezole Anaesthesia 
Dihydroergotamine Migraine 
Mianserin Antidepressant 
Mirtazapine Antidepressant 
Phentolamine Erectile dysfunction 
Phenoxybenzamine Hypertension 
Data adapted from http://ardb.bjmu.edu.cn/default.htm. 
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2.1.8. Molecular properties of α2-ARs 
 
α2-ARs have high amino acid sequence similarity (~75%) in the seven trans-
membrane spanning domains. The TMs form the ligand binding pocket where 
agonists and antagonists bind (Figure 2.1.8.1). The structural differences  
between the subtype TMs presumably create selectivity among α2-ARs [57]. 
The intra- and extracellular regions are much more divergent, especially the 
third intracellular domain [58]. The second intracellular and third intracellu-
lar domains are important in G protein coupling. α2a- and α2c-AR are N-
terminally glycosylated. α2a- and α2b-AR carry C-terminal Cys residues that 
can be palmitoglated. Mutation studies indicate that glycosylation and palmi-
toylation do not affect receptor G protein coupling, localisation or receptor 
trafficking [59]. 
 
 
 
Figure 2.1.8.1: Proposed key interactions between one catecholamine hor-
mone, (R)-epinephrine, and α2a-AR, in the inactive (plain fonts) and active 
(both bold and plain fonts) [60]. The most conserved residues in TMs are 
marked as number TMX.50, and amino acid residues within a given TM are 
then numbered relative to this position. The key residues are marked ac-
cording to this scheme. 
 
The predicted three-dimensional structures of α2-ARs are based either on 
hydrophobicity plots or molecular modelling, using the bovine rhodopsin x-
ray structures [2-4], the frog rhodopsin cryo-EM structure [61] or bacterial 
rhodopsin x-ray structures as a template – although rhodopsin and bacteri-
orhodopsin have different structures. One of the most frequently used is 
Joyce Baldwin’s Cα trace-model [62] which integrates structural information 
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from nearly five hundred GPCR primary sequences with the frog rhodopsin 
three-dimensional model [61]. The model allows the assignment of the 
transmembrane sequences and provides a static starting model of individual 
α2-ARs for molecular dynamics, pharmacophore and rational drug design 
studies. As the amino acid sequence homology of the extramembranous loops 
of α2-ARs is low, it is likely that each folds differently, making molecular 
modelling of extramembranous loop structures challenging. 
 
The ligand binding pocket for GPCR family A amine receptors is located    
between the TMIII, TMVI and TMVII; and functional, spectroscopic and 
structural data suggest that agonist activation of the family A amine receptor 
members is caused by the movement of these TMs with respect to each 
other [19-23]. Several α-ARs structural models are consistent with site-
directed mutagenesis, ligand binding and other functional data (Figures 
2.1.8.1 and 2.1.8.2). These data describe the key interactions between the 
amino acid side chain of human α-ARs and several ligands for the inactive 
and active receptor conformations. However, subtype specific drug design of 
α-ARs based on the current set of models is somewhat limited due to the 
lack of understanding regarding the empirical structures of active, inactive 
and intermediate state conformations of α-ARs. 
 
In the α2-ARs, the emerging agreement is that the 2i, amino and carboxyl 
termini of 3i and carboxyl terminus are important for G protein activation and 
binding. All α2-ARs have a long 3i, with low amino acid sequence similarity, 
but of equal size [58]. The α2b-AR 3i is important for receptor phosphoryla-
tion, desensitization, and internalization processes after agonist binding and 
activation [42,63-67]. For instance, the 3i Gly213–Gly354 region is required 
for microtubule sorting of α2b-AR to the cell surface [42], while the con-
served polyglutamate region (residues Glu299–Glu319) is required for short-
term agonist-promoted phosphorylation and resulting desensitization of α2b-
AR [66,67]. Variations of the conserved polyglutamate region in α2b-AR 3i 
correlates with a genetic risk factor for acute coronary events in humans 
[68]. The 3i loop can interact with several protein ligands, such as spino-
philin, β-arrestins, and 14-3-3-ζ [63,64]. The proposed interactions       
between α2b-AR and β-arrestins and 14-3-3- ζ are in the carboxyl terminal 
half of the 3i, whereas the spinophilin binding sites are located at the        
extreme ends of the 3i loop [63,64]. 
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Figure 2.8.1.2: Amino acid sequence and secondary structure model of human 
α2b-AR. The lipid bilayer is indicated by shaded box. The circles represent 
amino acids (single-letter code). Amino acid residues that are conserved 
among α2-ARs are shown as yellow circles; the corresponding amino acid 
residues that are functionally important for phenethylamine interactions with 
α2a-AR are shown as blue circles [60]. Cystein residues in the 1e and 2e 
form a disulphide bridge that is shown as a yellow line. The most conserved 
residues in TMs are marked as number TMX.50, and amino acid residues 
within a given TM are then numbered relative to this position. The key resi-
dues are marked according to this scheme. A, B and C are the various       
regions of α2a-AR thought to activate different G proteins based on 
mutagenesis and peptide-activity data; A, selective G protein activator (RY-
WSITQAIEYNLKRTPR); B, low-potency non-selective G protein activator 
(RITQIAKRRTR) and C, selective Gi/Go activator (KASRWRGRQNREKRFTF) 
[69,70]. 
 
2.2. Recombinant expression, purification and crystallization of GPCRs 
 
Structural characterization of a protein may be obtained using different bio-
physical and biochemical techniques. Usually these approaches require sev-
eral milligrams of pure protein. X-ray crystallography is the most accurate 
technique for structural characterization of a protein at high resolution (2.5 Å 
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or more) [71]. For such x-ray analysis a pure protein has to be crystallized. 
Consequently, membrane protein crystallization is one of the most challeng-
ing tasks in biological crystallography. While over 30,000 protein structures 
have been solved, less than 200 hundred are membrane proteins 
(www.rcsb.org/pdb/; [72]), and, the only GPCR solved at high resolution is 
bovine rhodopsin [2-4]. 
 
There are several reasons for this: firstly, expression levels of recombinant 
membrane proteins are usually very low, and, as a result, sufficient material 
for purification and crystallization is difficult to obtain. Secondly, the amphi-
pathicity of membrane protein requires the use of appropriate detergents that 
cause difficulties in protein purification and activity. Thirdly, crystallization 
of membrane proteins is often a difficult process. Finally, the diffraction 
quality of membrane proteins is often poor and resolution is low due to 
structural heterogeneity and disorder. 
 
2.2.1. Prokaryotic host systems 
 
Since the late 1980s great efforts have been made to develop heterologous 
over-expression systems for GPCRs (for reviews, see [73,74]). Prokaryotic 
expression systems, especially Escherichia coli, have been widely tested for 
GPCRs ([74]; Table 2.2.2.1). 
 
Escherichia coli is inexpensive to grow and easy to scale-up, but there are 
several problems for over-expression of GPCRs and other eukaryotic mem-
brane proteins because it is a prokaryote. First, eukaryotic membrane pro-
teins may require post-translational modifications and processing for correct 
folding and activity, such as glycosylation, fatty acid acetylation, phosporyla-
tion and eukaryotic transmembrane protein insertion/folding that prokaryotic 
cells can not perform. Secondly, the lipid composition of the E. coli mem-
brane is different that of mammalian cells; the lipid composition influences 
the insertion and the activity of membrane proteins [75,76]. Thirdly, codon 
usage in E. coli and mammalian cells is different; the percentage of low-
abundant codons can reduce both the quantity and quality of the recombinant 
protein, such as truncated forms of the synthesized protein [77]. Fourthly, 
some recombinant proteins turn out to be toxic to the prokaryotic host cells. 
Fifthly, recombinant proteins, especially membrane proteins, may misfold due 
to the lack of appropriate folding machinery and accumulate into so-called 
inclusion bodies in the cytoplasmic space of E. coli [78]. Occasionally, how-
ever, the inclusion bodies can be refolded to the functional protein. 
 
Several GPCRs have been functionally expressed in E. coli. The expression 
levels have usually been very modest, although there are some exceptions: 
the rat neurotensin receptor has been expressed at relatively high levels 
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(more than ten pmol per mg) and production has been successfully scaled up 
to milligrams level per batch [79]. The muscarinic M1 receptor has also been 
expressed at relatively high levels and purified in milligram amounts [80]. 
Rat α2b-AR has been functionally expressed in E. coli with low expression 
levels (280 fmol/mg), but human α2b-AR was accumulated in inclusion bodies 
[81,82]. Very recently Roosild and co-workers used the Bacillus subtilis 
Mistic protein as a fusion partner for high-levels production of a GPCR and 
other eukaryotic membrane proteins in prokaryotic cells [83]. 
 
Halobacterium sal narum is a member of the Archaea, an evolutionary distinct 
group from the Eubacteria and Eukaryota. β
i
2-AR has been expressed in H. 
salinarum and Haloferax volcanii (Bmax’s were at sub-pmol/mg levels). The 
mRNA levels and immunological analysis suggested relatively high levels of 
gene and protein expression [84]. 
 
2.2.2. Eukaryotic host systems 
 
For most GPCRs, the recombinant expression levels do not exceed ten pmol 
per mg of membrane protein fraction and/or the receptor is non-functional 
(Table 2.2.2.1). Consequently, eukaryotic expression hosts have to be con-
sidered. Although there are a variety of different alternatives available, the 
most commonly used are: yeasts, filamentous fungus, insect cells, plant cells 
and mammalian cell lines, either by construction of stable/semi-stable cell 
lines or by viral-meditated expression. For ligand binding screens or func-
tional assays, expression levels 1-10 times those observed in native 
cells/tissues are sufficient (i.e. 1-100 pmol per mg of membrane protein 
fraction). For structural studies - which require purification to homogeneity, 
see below – several hundreds of picomoles per mg expression levels (several 
milligrams per liter of culture) are minimally required; otherwise efforts are 
rather, as Patrick Loll nicely put it, “heroic (or at least expensive)” [85].  
Below, I will introduce the general features of the most frequently used    
eukaryotic hosts (for a more thorough review, see e.g. BBA biomembranes, 
volume 1610(1).) 
 
Yeasts, mainly Saccharomyces cerevisiae, Schizosaccharomyces pombe and 
especially the methylotrophic Pichia pastoris, have been used for recombi-
nant over-expression of various GPCRs [73,74,86]. Relatively high expres-
sion levels (more than 20 pmol per mg) have been reported for α2 and β2 
adrenergic receptors, serotonin 5-HT5A, and dopamine D2 [86-89]. Yeasts 
are able to carry out the majority of the eukaryotic post-translational modifi-
cations. However, over-glycosylation and ineffective N-glycosylation in 
some yeast strains are well documented. 
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Stable recombinant and baculovirus infected insect cells have been success-
fully used for expression of α/β adrenergic receptors, dopamine receptors, 
serotonin receptors, muscarinic receptors and opioid receptors ([73,90];  
Table 2.2.2.1). Insect cells grow easily in serum-free suspension, and the 
system can be scaled up. The most often applied approach is use of recombi-
nant Autographa californica nuclear polyhedron baculoviruses [91]. In this 
system, the cDNA of interest is cloned into a carrier plasmid that is inserted 
into the genome of the baculovirus by homologous recombination. In the bac-
to-bac system, the cDNA of interest is cloned into a carrier vector and 
transfected into E. coli cell strains that contain a parent bacmid vector. Spe-
cific transposition takes place between the pFastBac vector elements and the 
parent bacmid vector in the presence of the transposition proteins coded by a 
helper plasmid. The isolated recombinant bacmid DNA is transfected into 
Spodoptera frugiperda cells, where recombinant Baculovirus particles will be 
produced. These are further used for amplification of viral stock and protein 
expression. Baculovirus only infects and replicates in insect cells, thus      
reducing the potential biosafety risk. Spodoptera frugiperda (Sf9 and Sf21), 
Trichoplusia ni, and Estigmena acrea are the most widely used insect strains, 
and they are all commercially available as kits. There are several promoters 
for high-level expression reported; the most commonly used is the polyhed-
rin promoter, which can express foreign protein at up to 20% of the total cel-
lular protein synthesis. Insect cells are able to complete most mammalian 
post-translational modifications. However, N-glycosylation and high-
mannosylation have been reported to be immature or incomplete [92]. Very 
high expression levels and/or a requirement for extensive post-translational 
modifications can cause structural heterogeneity of recombinant protein in 
the late phase of infection since the endoplasmic reticulum and Golgi appara-
tus are saturated. Also, the protein synthesis and secretion pathways of the 
host cells are inhibited [92]. This problem is general for all the viral       
systems. 
 
Finally, mammalian cell host systems by definition yield the most native-like 
GPCRs. Various stable and semi-stable/transient cell lines expressing GPCRs 
have been reported (Table 2.2.2.1). These are sufficient for ligand binding 
and other biochemical characterizations, but high-level expression for bio-
physical studies is only possible using one of the several viral systems avail-
able, because otherwise the expression level is too low. However, some 
mammalian viral systems have potential biosafety risks. The most widely 
used for GPCRs are based on the alphavirus, Semliki Forest virus (SFV) [93]. 
Alphaviruses are enveloped virus particles with single-stranded RNA       
genomes. Other occasionally used viral systems are based on vectors from 
Sindbis virus, Venezuelan Equine Encephalitis virus and Vaccinia virus. 
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The SFV expression system is based on two plasmid vectors containing      
genomic SFV cDNA: the SFV expression vector and the SFV helper vector 
[93]. The expression vector carries the SFV non-structural genes, the 
strong promoter (26S) and a multilinker cloning region for the introduction of 
the recombinant protein gene. The SFV helper vector contains the structural 
proteins of SFV (the viral capsid and envelope). Co-transinfection of in vitro 
transcribed recombinant and helper RNA into mammalian cells generates 
high-titer recombinant particles that are capable of infecting various mam-
malian cells and other higher eukaryotic cell lines. Due to lack of the RNA 
packing signal in the recombinant RNA, no helper RNA is packaged. There-
fore, upon infection of host cells, no secondary infection is possible, but rapid 
and high-level transgenic expression will occur. So far, several hundreds of 
GPCRs have been tested [93,94]. The highest expression values reported 
are ca. 250 pmol/mg, with a production yield of milligrams per liter of mam-
malian suspension cultures [95,96] (Table 2.2.2.1). This is 10-100 times 
lower than the expression levels of bacteriorhodopsin and bovine rhodopsin 
in their specific membranes. Production costs for SFV are typically between 
500 and 1000 €/liter of cultivation because of the costs of in vitro mRNA 
transcription and serum containing media. 
 
Table 2.2.2.1: Examples of recombinant GPCRs over-expression. 
Hosts Nº of 
GPCRs 
tested 
Major advantages Major disadvantages Maximum expres-
sion levels re-
ported [activity/mg 
of membrane frac-
tion] 
Eubacteria     
Escherichia coli >10 fast, several expression vectors 
and strains available (Gateway™), 
very easy to scale-up, cost effec-
tive, no biosafety risk, Se-
methionine competent, membrane 
specific strains available (C41-43; 
[97]) 
refolding usually required, synthe-
sized membrane proteins are often 
toxic to bacteria, lack of enzymes 
responsible for post-translational 
modifications       (effects on fold-
ing and/or function) 
15 pmol/mg 
[79,80] 
Archeae     
Halobacterium salina-
rum and Haloferax vol-
canii 
<10 easy to scale-up, cost effective, no 
biosafety risk, low contamination 
risk, Se-methionine competent, 
analogous structures to GPCRs 
solved 
cloning more demanding than E. 
coli, only few expression vectors 
available, no glycosylation 
180 fmol/mg [84], 
40 pmol/mg  
(unstable, study I), 
9 mg/l (bR-α2b-AR 
fusion, study II) 
Eukaryota     
Yeast (Saccharomyces 
cerevisiae, Schizosac-
charomyces pombe and 
Pichia pastoris) 
>50 several expression vectors and 
strains available (Gateway™), easy 
to scale-up, cost effective (5x E. 
coli), yeasts perform many of the 
post-translational modifications, no 
biosafety risk 
slow, improper N-glycosylation, 
high mannosylation, thick cell wall, 
cloning and clone selection more 
difficult than E. coli 
350 pmol/mg [98] 
Insect cells (stable and 
viral with baculovirus) 
<100 several expression vectors and 
strains available (Gateway™), high 
level of expression, correct folding, 
post-translational modifications 
more difficult to work with, rel-
atively expensive, slow generation 
time, not suitable for proteins with 
repetitive sequences, possible 
360 pmol/mg [99] 
similar to those in mammalian cells, 
cost effective (10-20xE. coli) 
contamination risk 
Mammalian cells (tran-
sient) 
>500 several expression vectors and cell 
types available (Gateway™) 
transinfection cell specific, expen-
sive, expression levels not suit-
able for structural studies, expen-
sive (10-100xE. coli) 
<50 pmol/mg (nor-
mally 1-10 
pmols/mg) 
Mammalian cells (sta-
ble) 
>500 several expression vectors and cell 
types available (Gateway™), induc-
ible 
slow, expensive, stability, expres-
sion levels not suitable for struc-
tural studies 
<50 pmol/mg (nor-
mally 1-10 
pmols/mg) 
Mammalian (Viral) >200 fast, broad host range, high level of 
expression, scale-up 
expensive (>100xE. coli), potential 
risk of biosafety, not robust (in vi-
tro mRNA transcription) 
287 pmol/mg [94] 
Others     
Cell-free translation β2-AR, 
domains 
of α2-ARs
Fast, simple low yields, expensive (>100xE. 
coli), expression levels not suit-
able for structural studies 
<pmol/mg [64,94] 
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For (Gateway™), see section 2.2.4. 
 
2.2.3. Purification and crystallization of GPCRs 
 
After production, the membrane proteins need to be isolated for crystalliza-
tion. A typical purification procedure requires several steps such as removal 
of cultivation media, disruption of cells, enrichment of the specific mem-
branes without use of detergent, solubilization by detergent(s), single or 
multiple purification steps (e.g. by using an ion-exchange, antibody affinity, 
metal affinity, ligand affinity and/or hydrophobic interaction affinity chroma-
tography), final polishing (e.g. gel filtration chromatography or isoelectric  
focusing) and possibly reconstitution into phospholipid vesicles. 
 
The proper choice of the detergents or mixture of different detergents is one 
of the most important issues. The native lipid bilayer surrounding the mem-
brane protein must be replaced with detergent molecules during purification 
and crystallization. Unfortunately, membrane protein activity and stability 
may alter in detergent solution, presumably because the detergents perturb 
the three-dimensional structure. Solutions used in purification and crystalli-
zation processes have to include detergents above the critical micelle con-
centration. This may make the overall cost of purification very high. Deter-
gents may interfere directly with the collection of NMR spectra and indirectly 
with x-ray crystallography (crystallization and data-collection steps) or 
cryo-EM (crystallization and freezing steps). Hundreds of different deter-
gents have been tried. One of the most effective ways of testing has been to 
screen a large number of detergents, since detergents interact uniquely with 
different membrane proteins. Small amphipathic polymers (amphipols), can 
also be tried as alternatives [100]. 
 
The generally used detection and purification tags for soluble proteins are 
also suitable for membrane proteins. These include poly-His, glutathione-S-
transferase, Green Fluorescent Protein (GFP), maltose-binding protein, 
“Flag” peptide, Tandem Affinity Purification (TAP) tags, all of which can be 
fused either to termini or internally. In addition, successful targeted selection 
and mutagenesis requires fast and parallel cloning and expression systems. 
There are several useful “automatic and semi-automatic” high-throughput 
cloning methods available [101], such as the Gateway systemTM. 
 
For crystallographic analysis, either two- or three-dimensional well-ordered 
crystals need to be obtained. Two-dimensional membrane protein crystals 
can be obtained directly from the phospholipid bilayer. These crystals are 
suitable for structural determination by cryo-electron microscopy. Several 
membrane proteins have been solved utilizing cryo-EM at low resolution 
(less than 5 Å); the maximum resolution obtained so far is about 3 Å for bR 
[102]. For x-ray analysis, a three-dimensional crystal needs to be obtained. 
 
The majority of membrane protein structures are solved by the standard   
vapour diffusion methodology in the presence of detergent(s) using standard 
hanging and sitting drop set-ups (www.mpibp-
frankfurt.mpg.de/michel/public/memprotstruct.html#a, 
http://sb20.lbl.gov/cobessi/membrane_struc.htm and 
http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html). The most suc-
cessful precipitants are the same as for soluble proteins: polyethylene glycol, 
polyethylene glycol monomethylether, ammonium sulphate and phosphate 
salts. The most successfully used detergents are octyl-β-D-glucopyranoside 
and dodecyl-β-D-maltoside. The amphipathic nature of the membrane pro-
tein:detergent complex means that only two basic types of three-dimensional 
crystals are allowed (type I and type II), of which most membrane protein 
crystals belong to type II (for a detailed description, see [103]). The crystal-
lization conditions have to maintain the hydrophobic domains in a native-like 
“membrane environment” while at the same time solvating the polar non-
membranous domains. Both of these aspects complicate membrane protein 
crystallization when compared to soluble protein crystallization. 
 
There are several approaches for the screening of membrane protein-
detergent complex crystallization conditions as well as selection of deter-
gents for crystallization described in the literature. Crystallization robots al-
low reproducible use of nanoliter volumes, which helps large-scale crystalli-
zation screening and optimization [104]. Unfortunately, the conventional ap-
proach is far from universally successful and so novel methodologies and de-
tergents are needed to overcome the difficulties in membrane protein crys-
tallization. 
 
In 1996, Ehud Landau and Jurg Rosenbusch [105] introduced a totally differ-
ent crystallization strategy, the in cubo method. This method uses the ten-
dency of certain monoolein lipids to form space-filling meso-phases in     
detergent:protein-precipitant-water mixtures (60%:40%), one of which is the 
cubic phase. The lipidic cubic phase (LCP) is better than conventional deter-
gent solubilisation for proteins because it provides membrane-like physico-
chemical properties such as lateral pressure, which is believed to be impor-
tant in maintaining the native integrity of membrane proteins. A number of 
alpha helical transmembrane proteins have crystallized and diffracted to near 
atomic resolution using LCP. In addition to ground-state and intermediates of 
bR [8], LCP has been successful for halorhodopsin, sensory rhodopsin II and 
two photosynthetic reaction centres [106]. There are, however, technical 
difficulties with the in cubo approach; the monoolein is not fluid at room tem-
perature, and the final protein-solution:monoolein matrix (40%:60% w/w) is 
extremely viscous, making all manipulations and automation very difficult. In 
addition, noncoloured proteins are difficult to recognize when the matrix 
 - 43 -
contains salts, liquid drops and non-continuous areas, all of which are seen 
in typical in cubo setups [106]. 
 
More recently, Salem Faham and James Bowie [107], described a bicelle-
lipid-detergent (BLD) crystallization method for bR; they obtained bR crys-
tals that diffracted to near atomic resolution using a dimyristoyl phosphotidyl 
choline-dihexanoyl phosphotidylcholine-β-octylglucopyranoside matrix. In 
BLD, membrane proteins are incorporated into small lipid-containing bilayer 
disks – bicelles – where they are in a more membranous-like environment 
than in detergent micelles [108]. Interestingly, the bicelle-lipid-detergent 
mixture is a solution at low temperature (below +4°C) and forms a clear gel-
type matrix at high temperatures (above ambient temperature). This allows 
crystallization using conventional crystallization screen tools. 
 
Both the in cubo and BLD methods have been recently tested with detergents 
and precipitates as well as new lipids which allow use of different tempera-
tures and lipid-phase-matrix formations [109-111]. So far only a few crystal 
structures have been reported using these crystallization media. 
 
2.3.4. Structural genomics of membrane proteins 
 
There are currently several networks working with structural genomics of 
membrane proteins, such as the European Membrane Protein Network (E-
MEP; www.e-mep.org), Membrane Protein Network (www.mepnet.org), 
Japanese Membrane Protein Network, National Centre of Competence in Re-
search Structural Biology (NCCR; www.structuralbiology.ethz.ch), Postge-
nomic Research and Technology in South-West Sweden (Swegene; 
www.molbiotech.chalmers.se/swegene/). The target selection among these 
networks varies: some have selected the so-called “species-specific”      
approach that deals with all membrane proteins from different species such 
as the extremophile Thermotoga maritima or the eukaryote Caenorhabditis 
elegans, while other networks have selected the “protein-specific” approach 
that deals with a particular type of membrane proteins such as GPCRs (MeP-
Net), bacterial reaction centres (Swegene) or transporters (NCCR). The 
membrane protein networks together with the soluble structural genomics 
consortiums will construct new methodologies that make automation, minia-
turization and parallelization possible. These methodologies will be very 
valuable in membrane protein production and crystallogenesis for structural 
analysis.  
 
Often using the natural sequence variations among the membrane protein 
homologs (para- and orthologs) or using mutagenesis has significantly      
improved membrane protein targets for expression, purification and crystalli-
zation [112-114]. For instance, George Schulz and his co-workers proposed 
 - 44 -
that well-ordered membrane proteins are difficult to obtain since the re-
quired of polar contact surface is too small. They enlarged the extramem-
banous polar surfaces by semi-random mutagenesis, and obtained well-
ordered crystals for x-ray analysis [114]. Alternatively, enlarged polar con-
tact surfaces can be obtained by co-crystallization with antibody fragments 
[115,116]. 
 
It is expected that, as membrane protein structural genomic work continues, 
data mining will make possible more efficient approaches for successfully 
selecting the target protein, for mutagenesis, and for expression. 
 
2.3. Intrinsically unstructured proteins: the third kingdom of proteins 
 
The structure-function-paradigm i.e. that three-dimensional structure is   
required for function is one of the central dogmas in protein science. How-
ever, numerous proteins appear to have large structural flexibility and little 
or no ordered structure when studied in vitro by nuclear magnetic resonance 
(NMR), small angle x-ray scattering, circular dichroism spectroscopy, light 
scattering and analytical ultracentrifugation [117-120]. These proteins can 
be separated into two distinct categories. The first category includes the 
molten globular proteins that have secondary structure elements but large 
structural flexibility. Members of the second category include proteins that 
behave almost like random coils. These proteins are called intrinsically     
unstructured or natively unfolded/disordered proteins (IUPs). It has been 
shown that many IUPs and IUP-like domains have regulatory roles in basic 
cellular processes such as transcription, translation, signal transduction and 
the cell cycle, suggesting that structural disorder is essential in these cellular 
processes [118,121]. IUPs and IUP-like domains may offer advantages for 
structural recognition by allowing high specific target selection with low    
affinity. IUP and IUP-like domains can interact with various different targets 
[121,122]. The number of IUPs and IUP-like domains identified so far       
includes hundreds of proteins 
(http://compbio.iupui.edu/dunker/html/www/Datasets/Disordered.htm). The 
number will most probably increase, as 33% of eukaryotic, 2% of Archaean 
and 4% of eubacterial proteins may carry IUP-like domains [121]. Interest-
ingly, some IUPs and IUP-like domains are associated with neurodegenera-
tive disorders [118,123-125] and cancer development [122]. 
 
IUPs differ from the structures deposited in the protein database (PDB; 
www.rcsb.org/pdb/; [72]) in amino acid composition, sequence complexity, 
hydrophobicity, charge and flexibility [119]. The IUPs have unusually large 
net charge at neutral pH and low content of hydrophobic amino acids. Not 
surprisingly, IUPs have specific amino acid distributions, with low amounts of 
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Asn, Cys, Ile, Leu, Tyr, Trp and Phe and high amounts of Gln, Glu, Lys, Ser 
and Pro compared to proteins of known structure (Table 2.3.2). 
 
Table 2.3.2: Amino acid frequencies of data sets of ordered and disordered 
proteins.  
Amino acida Globularb Swiss-Protb IUPb
Ala 8.15 7.62 7.15
Cys 1.64 1.62 0.61
Asp 5.78 5.25 5.05
Glu 5.98 6.47 14.26
Phe 3.95 4.10 1.66
Gly 7.99 6.85 4.31
His 2.33 2.25 1.15
Ile 5.43 5.85 3.67
Lys 5.43 5.97 10.43
Leu 8.37 9.54 5.44
Met 2.03 2.37 1.30
Asn 4.66 4.36 2.06
Pro 4.61 4.89 12.07
Gln 3.69 3.93 4.46
Arg 4.61 5.19 4.21
Ser 6.31 7.08 6.91
Thr 6.15 5.57 5.14
Val 7.00 6.61 8.02
Trp 1.55 1.21 0.32
Tyr 3.64 3.16 1.42
aAmino acid frequencies are in %. 
bData is adapted from [120]. 
Bold are significantly enriched and italic depleted when IUPs are compared 
with folded proteins in the PDB. 
 
Many of these properties are used to identify IUPs and IUP sequences from 
the proteins of known structure: the Foldindex server 
(http://bip.weizmann.ac.il/fldbin/findex) uses a combination of both the hy-
drophobicity and the net charge of the amino acid sequence[119]. There is 
also a neuronal network predictor (PONDR; http://www.pondr.com/) based on 
primary amino acid sequence and composition [118], and one (DisEMBL) 
based on loops and missing coordinates in the PDB [126]. 
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3. 
 
Aims of the study 
 
he specific aims of the study described herein were: 
 
 
 
T
 
 
(1) To produce α2b adrenoceptor – bacteriorhodopsin (α2b-AR-bR) fusion 
proteins in H. salinarum and compare the H. salinarum production system to 
other high level production systems. 
 
(2) To purify and crystallize α2b-AR-bR fusion proteins for functional and 
structural characterization. 
 
(3) To study the functional role of the third intracellular domain (3i) of α2b-
AR, and to determine which parts of α2b-AR 3i influence ligand binding and G 
protein coupling. 
 
(4) To study the occurrence and role of intrinsic unstructured regions in α2b-
AR and other human GPCR extramembranous domains. 
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4. 
 
Materials and methods 
 
etailed descriptions of the materials and methods used can be found in 
the original communications I-IV (Table 4.1). Strains and plasmids 
used in the study are listed in Table 4.2. 
 
D 
Table 4.1: Methods used in the study. 
Method i  Used n paper
Molecular biology  
DNA sequencing I, II and IV 
mRNA detection and analysis (North-
ern blotting)  
I 
Molecular cloning techniques I, II and IV 
Protein  
Affinity chromatography II 
Bradford assay I, II and IV 
Membrane protein crystallization II and unpublished (see below) 
Immunostaining (Western blotting) I, II and IV 
Amino terminal protein sequencing II 
Size-exclusion chromatography  II 
SDS PAGE/native PAGE I, II and IV 
Sucrose gradient purification II 
Binding assays  
[35S]GTPγS binding IV 
[3H]Radioligand binding I, II and IV 
In silico analysis  
Database search and analysis III 
Protein sequence prediction and mod-
elling 
III and IV 
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Table 4.2: Strains and plasmids used in the study. 
Strain i  Used n paper
Escherichia coli JM109 I, II and IV 
Halobacterium salinarum L33 I and II 
Saccharomyces cerevisiae SC261 I 
CHO-K1 IV 
Plasm d i  
eGFP-C1 II and IV 
pHEX I and II 
pXLNov-R II 
pUC19 I, II and IV 
pREP4 IV 
 
4.1. Crystallization by the bicelle-lipid-detergent method (Study II and unpub-
lished) 
 
bR constructions (G. Turner et al., unpublished). Construction of the expres-
sion vectors containing wild-type bR and bR containing the D85N mutation 
has been described previously [127]. Two second-site mutants, T121V and 
Y185F, were introduced into the D85N background by PCR mutagenesis    
essentially as described previously [128]. The two carboxy-terminal dele-
tion mutants were constructed using oligo-directed mutagenesis (Turner et 
al., in preparation). The carboxy-terminal truncations were accomplished by 
separately replacing codons 229 (TGAI∆229-248) and 238 (TGAII∆238-248) with a 
premature translation stop codon (TGA). The wild-type and mutated bR con-
structs were subcloned into halobacterial expression vectors and trans-
formed into H. salinarum strain L33 (Vac_, Rub_, bR_). Individual transfor-
mants were isolated from selective solid media and used to establish prepa-
rative non-selective cultures. 
 
Purification. Membranes containing pure bR were isolated from transgenic H.
salinarum L33 strains as described previously [127,128] with the following 
modifications. Purple membrane fractions from a standard linear sucrose 
density gradient were diluted 1:1 in buffer A (25 mM KH
 
2PO4/K2HPO4, pH 
7.4), applied to a second sucrose density step gradient (with 5 ml of 50% of 
sucrose, 7 ml of 40% sucrose, and 7 ml of 25% sucrose) and centrifuged for 
16 h at 28,000 rpm in an SW28 rotor (Beckman). Membranes banding at the 
interface between 40% and 50% sucrose were collected. Sucrose was       
removed by dilution with buffer A followed by ultracentrifugation. Mem-
branes were resuspended in buffer A, and bR concentrations were deter-
mined by absorbance spectroscopy using a Hitachi U-2001 spectrophotome-
ter with εbR568=62,700 /Mcm [129]. The ultrapure bR samples were adjusted 
to 20 mg/ml in buffer A. 
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 Crystallization. A water-lipid-detergent mixture (60%:30%:10%) (water: 1,2-
Dimyristoyl-sn-Glycero-3-Phosphocholine, Avanti Polar Lipids, U.S.A.: 
CHAPSO (3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-
propane sulfonate), Anatrace Inc, U.S.A.) was mixed in ratio of 4:1 with pro-
tein solution (20 mg/ml). All solutions were kept on ice prior to mixing to 
keep the mixtures fluid. Conventional sitting and hanging drop vapour diffu-
sion methods were employed at 310 K. Typically, the crystallization drops 
contained 4 µl of protein/bicelle solution, with 1.5 µl of reservoir solution and 
0.5 µl of 2.2% β−OG (n-octyl-β−D-glucopyranoside, Anatrace Inc, U.S.A.). 
We tested crystal screens I and II (Hampton Research, U.S.A.), and bR crys-
tallization conditions with phosphate salts as precipitant [105,107]. We also 
tested the cloud-point-based crystal screen I and II [130] without the bicelle 
component. Well-ordered crystals grew from 4 µl of protein, 1.5 µl 3.5 M 
Na2HPO/NaH2PO4, pH 5.6, 0.5 µl 2.2% β-octylglucoside over a period of 14 
days at 310 K. 
 
4.2. Data collection and structure solution (unpublished) 
 
Crystals were mounted in nylon loops (0.05-0.1 mm diameter, 10.0 micron; 
Hampton Research, U.S.A.) and flash-cooled to 100 K. For the bR double 
mutant (bR D85N/T121V) and TGAI∆229-248, data sets to 2.3 Å and 3.5 Å 
resolution, respectively, were collected on a MAR CCD detector at the      
microfocus beam line ID13 (ESRF, Grenoble, France). Wild-type and a sec-
ond TGAI∆229-248 data set were collected at the beam line BW7A (DESY, 
Hamburg, Germany). In addition, wild-type crystal form II and bR-α2b-AR 3i 
(203-292) chimera were tested either on a R-AXIS IV image plate using Cu 
Kα radiation generated by a Rigaku RU-300 rotating-anode or on the syn-
chrotron beam lines ID13/BW7A. All diffraction data were indexed, pro-
cessed, and scaled using the HKL 1.97.2 suite [131]. 
 
Molecular replacement of wild-type bR and bR D85N/T121V were performed 
using AMoRe from the CCP4 program package [132] with PDB code 1C3W 
as the search model. Refinement of the models was done with SHELX97 
[133], and took merohedral twinning (fraction of 0.44) into account [134]. 
The model building was performed in O. The quality of the final model was 
analyzed using PROCHECK [135]. 
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5. 
 
Results and discussion 
 
elow, I will review the main  results and implications of this work, 
largely based on published original communications I-IV. A more 
comprehensive discussion can be found in the original communica-
tions. 
B 
 
5.1. Production of α2b-AR variants in H. salinarum (Study I) 
 
Our first strategy to study α2b-AR production in H. salinarum involved fusing 
the coding region of the human α2b-AR gene to nucleotide sequences in-
volved in the regulation of bop gene transcription and translation. We engi-
neered 30 combinations of α2b-AR-bR fusions with various amino and car-
boxyl terminal tag modifications and characterized their effect on RNA and 
protein levels (Table 5.1.1 and Figure 5.1.1). 
 
As the timing of bop-RNA and Bop/bR-protein production is coupled [136], 
we expected similar behaviour for the GPCR-bR chimeras. We therefore 
used the results of the GPCR-bop RNA induction analyses to determine when 
to collect cells for production. As the maximal GPCR-bop RNA levels were 
achieved between 40 and 70 h of culture growth, we harvested cells over 
this time period and isolated membranes for SDS-PAGE/immunostaining 
analysis and [3H]radioligand binding. 
 
Membranes isolated from H. salinarum cells expressing α2b-AR-∆3i-ID26 
(Table 5.1.1) fusion protein were recognized by the bR polyclonal antibody 
(Figure 5.1.2). The polyclonal antibody specifically recognizes the amino 
terminus of bR. We only observed α2b-AR-bR protein for some of the fusions 
that accumulated RNA, suggesting that receptors were expressed at levels 
below the antibody detection limits or that receptor accumulation was unsta-
ble. 
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Table 5.1.1: α2b-AR-bR fusion used in study I and their RNA levels. 
Fusion 
ID no. 
N-terminus1 Length of 3i2 C-terminus3 RNA level4
1 A WT WT - 
2 A WT HA - 
3 A WT HA-ClaI + 
4 A WT His6 - 
5 A WT His6-ClaI - 
6 A ∆3i-I (192-359) WT + 
7 A ∆3i-I (192-359) HA - 
8 A ∆3i-I (192-359) HA-ClaI + 
9 A ∆3i-I (192-359) His6 - 
10 A ∆3i-I (192-359) His6-ClaI - 
11 A ∆3i-II (218-357) WT + 
12 A ∆3i-II (218-357) HA - 
13 A ∆3i-II (218-357) HA-ClaI + 
14 A ∆3i-II (218-357) His6 - 
15 A ∆3i-II (218-357) His6-ClaI ++ 
16 B WT WT + 
17 B WT HA - 
18 B WT HA-ClaI + 
19 B WT His6 - 
20 B WT His6-ClaI - 
21 B ∆3i-I (192-359) WT + 
22 B ∆3i-I (192-359) HA - 
23 B ∆3i-I (192-359) HA-ClaI ++ 
24 B ∆3i-I (192-359) His6 + 
25 B ∆3i-I (192-359) His6-ClaI - 
26 B ∆3i-II (218-357) WT + 
27 B ∆3i-II (218-357) HA - 
28 B ∆3i-II (218-357) HA-ClaI + 
29 B ∆3i-II (218-357) His6 + 
30 B ∆3i-II (218-357) His6-ClaI - 
1A, 17 residues from bR are fused at the amino terminus of α2b-AR 3i; B, first 
TM helix (37 residues) from bR. 23i, third intracellular loop of α2b-AR; ∆3i-I 
(192-359), full deletion of 3i; ∆3i-II (218-357), deletion of middle part of 3i. 
3WT, unaltered; WT-HA, nine amino acids peptide epitope from the influenza 
hemaglutinin protein introduced after WT coding region; WT-His6, six con-
secutive histidine amino acids introduced after WT coding region;-ClaI, ClaI 
restriction site introduced after HA/His6 coding region. 4 - RNA was not ob-
served; + RNA was observed; ++ RNA was observed at levels higher than 
with other fusions. 
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Figure 5.1.1: α2b-AR-bR fusion proteins. Minimal fusion constructs A, where 
17 residues from bR are fused at the amino terminus of α2b-AR. This con-
tains the bR signal sequence and four additional amino acid residues. The last 
13 residues of α2b-AR were replaced with 32 residues from bR. Second set 
of constructs are indicated as B. In these, the first bR TM helix 1 replaces 
the α2b-AR TMI. The carboxyl terminus is as in A. Various purification tags 
(Table 5.1.1) were also added. In addition, two third intracellular deletions 
were cloned (∆3i-I and ∆3i-II). 
 
Membranes isolated from some of the α2b-AR constructs that produced sig-
nificant quantities of RNA and protein bound to the high affinity antagonist 
[3H]Rauwolscine, (Table 5.1.1 and Figure 5.2.1). For α2b-AR-∆3i-ID26, the 
Bmax level was about 40 pmol/mg of membrane protein, which is comparable 
to that found in S. cerevisiae (Table 5.1.2; [88]). Scatchard analysis, how-
ever, showed that the binding affinity is ten times weaker than that of wild-
type α2b-AR expressed in yeast or human cells (unpublished results). 
 
Table 5.1.2: Specific activity1 of α2b-AR expressed in H. salinarum (pmol/mg 
of protein). 
1Specific activities of isolated membranes were measured as the difference 
in radioactive [3H]rauwolscine bound in the presence and absence of 10 µM 
phentolamine. bR was used as a negative control and wild-type α2b-AR ex-
Constructions Controls 
ID62 ID11 ID21 ID26 bR 
(neg.) 
α2b-AR 
(pos.) 
11 5 24 40 2 39 
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pressed in yeast S. cerevisiae was used as the positive control. 2ID numbers 
are described in the table 5.1.1. 
 
 
Figure 5.1.2: Expression of α2b-AR in H. salinarum. A) Typical analysis of 
chimeric α2b-AR-bR RNA transcript. RNAs were harvested and isolated in 
early stationary phase, which corresponded to maximal levels of bop mRNA 
and bR (between 72 and 73 hs). RNAs were separated on a denaturizing aga-
rose gel, blotted onto a nylon membrane and detected with digoxigenin la-
beled probes specific for the α2b-ar gene and 7S rRNA; 7S rRNA probe was 
used for comparison. The positions of α2b-ar and 7S rRNA are indicated by 
arrows. B) Protein expression of α2b-AR-bR construct α2b-AR ∆3i-ID26. 
Cells were harvested and membranes were isolated after 72 h of inoculation. 
After SDS-PAGE, the proteins were transferred onto PVDF membrane, and 
immunostained with a serum against the bacteriorhodopsin N-terminus. The 
specific protein bands are indicated by arrows. Figure A is adapted from 
George Turner. 
 
The reduced affinity of the α2b-AR-∆3i-ID26 in H. salinarum might have 
several origins, such as the different lipid composition of H. salinarum mem-
branes or the modifications at the amino and carboxyl termini. However, the 
difference is not because of the 3i deletion, as [3H]Rauwolscine affinity was 
unperturbed for α2b-AR ∆3i expressed in human cells (Study IV, see 5.4). 
Moreover, preliminary studies with variants including either only the amino 
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or only the carboxyl terminus from bR demonstrated that only the amino ter-
minal, not the carboxyl terminal, modifications perturb α2b-AR ligand binding 
in CHO cells (unpublished results). This may be due to processing of the bR 
signal peptide in CHO cells. 
 
Several constructs showed RNA levels comparable to wild-type bop levels, 
but the protein levels were low or undetectable. This may be due to the dif-
ferent nucleotide composition of H. salinarum versus Homo sapiens. For    
instance organisms with GC rich genomes, such as plants, frequently require 
codon optimization for successful recombinant over-expression in E. coli 
[77]. The human and H. salinarum have different GC contents (51% and 68%, 
respectively), which is correlated with their codon usage [137]. The bop 
gene contains 17 (6.5% of 262 residues) low abundance (frequency <1%) H. 
salinarum codons, while the α2b-AR coding region contains 55 (12% of 450 
residues) such codons. The sRI of H  salinarum expresses at only 10% of bR 
levels under the bop promoter and control elements, demonstrating that, 
even for homologous expression, coding sequence and codon usage can sig-
nificantly influence protein levels. Efficient translation may play an important 
role in the extremely high level membrane protein production of bR in         
H. salinarum, and therefore may also be important for recombinant protein 
production in H. salinarum. 
.
i
 
Study I suggests that further optimization of the amino and/or carboxyl ter-
minal coding region of α2b-AR-bR constructs, codon usage and expression 
studies are necessary for high level production of α2b-AR in the H. salinarum 
system. 
 
5.2. GPCR domain over-expression in H. sal narum (Study II) 
 
We next constructed bop gene fusions where the 3i of α2b-AR was grafted 
into the 3i of bR. α2-AR 3i is interesting because it may contain protein 
ligand binding determinants [63,64]. Previous efforts to express this region 
in E. coli have been unsuccessful. A related strategy has been previously 
adapted for two other GPCRs: bovine rhodopsin and CC chemokine receptor 
(CCR5) [138,139]. 
 
Based on results from study I, all constructs included critical control ele-
ments for transcription and translation of wild-type bR. Two versions of six 
different chimeras were made, one with and one without a GFP fluorescence 
tag (Study II, Figure 1). Five of the chimeras successfully expressed (Study 
II, Table 2). The expression level of the best chimera was very high, ~9 mg/l 
liter. This level, more than 50% of wild-type bR levels, corresponds to more 
than 10% of the total membrane protein. It is much higher than in study I. 
 
 - 55 -
We found large variation in the expression levels between the chimeras 
(Study II, Table 2). The α2b-AR construct (3i 203-376) was not expressible, 
probably because of the unusual region between 292 and 376, which contains 
15 consecutive Glu residues (E294 to E311) and five Arg residues. This region 
is proteolytically sensitive: we observed proteolysis in the other expression 
systems using full length α2b-AR [140], while in H. salinarum, we did not de-
tect immunogenic fragments by SDS-PAGE/immunostaining analysis. Alter-
natively, the different codon usage and CG content between H. salinarum and 
human sequences contained in this region might have prevented successful 
expression in H. salinarum. 
 
5.2.1. Purification and spectroscopic characterization of chimeras (Study II) 
 
A major goal of this thesis was to purify enough functional full-length α2b-
AR, or domains of it, for crystallization and structure determination. While 
chimerical bR-α2b-ARs expressed at levels less than 10% of the total mem-
brane protein could be immunopurified [87,88], it was difficult to obtain suf-
ficient material this way for crystallization. However, I could purify chimeras 
expressed at levels greater than 10% of the total membrane protein by stan-
dard bR protocols. Therefore, I focused on bR-α2b-AR 3i (203-292) as its 
expression level was the highest, and it could be purified to near homogene-
ity by the sucrose density gradient centrifugation method (Study II, Table 2 
and Figure 5.2.1). Amino acid sequencing indicated that the amino terminus 
was blocked as in wild-type bR [141] suggesting that the signal sequence 
was correctly cleaved and the amino terminus was processed correctly. 
 
Making chimeras, as described here, is a convenient method to study how 
extramembranous domain regions may contribute to seven transmembrane 
spanning protein functions. The bR-α2b-AR 3i (203-292) chimera had a 
properly folded bR domain allowing spectroscopic investigation of photo-
chemical activity. The 89 amino acid 3i loop insertion changed ground-state 
and light-induced intermediate state transitions only a little, as seen from the 
dark adaptation kinetics and kinetics of the M-intermediate and proton trans-
fer (Study II, Table 3). The retinal chromophore binding pocket was therefore 
not severely affected by the loop region insertion. 
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Figure 5.2.1: Purification of bR-α2b-AR 3i using sucrose density gradient. A) 
Absorption spectra of purified bR-α2b-AR 3i (203-292), the high-density 
fraction from sucrose gradient (Vtot 3i=5 ml; Vtot bR=15 ml) was diluted 1:10. 
B) SDS PAGE: lane 1, 10 µl of purified wild-type bR; lane 2, Molecular 
weight standards; and lane 3, 10 µl of purified bR-α2b-AR 3i (203-292). The 
gel was stained with Coomassie brilliant blue R- 250. C) Sucrose density 
gradient purification: wild-type bR (left), recombinant wild-type bR (middle) 
and bR-α2b-AR 3i (203-292) (right). The high density band (indicated by the 
arrow) is the purified bR fraction. 
 
The expression, production and purification results from study II demonstrate 
that bR and H. salinarum can be used as high level production machinery for 
the GPCR extra-membranous domains in their “native” heptahelical trans-
membrane framework. This allows detailed biochemical and biophysical 
characterization of important parts of GPCRs, including crystallization and 
structural studies. 
 
5.2.2. Crystallization and structural characterization of wild-type bR, bR     
mutants and bR-α2b-AR chimeras (Study II and unpublished) 
 
Initial crystallization trials of bR-α2b-AR 3i (203-292) yielded morphologi-
cally hexagonal crystals (Figure 5.2.3.1). The crystals diffracted to a maxi-
mal resolution of 15 Å on a rotating anode generator using our local x-ray 
source. It is not yet clear whether the apparent disorder originates from in-
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clusion of the large 3i loop. Accordingly more optimized crystals of bR-α2b-
AR 3i (203-292) must be generated, possibly by co-crystallization with the G 
proteins or other α2-AR 3i partners, and collected at a third-generation syn-
chrotron source. 
 
I crystallized wild-type and several bR mutants. Well-diffracting primitive 
monoclinic bR crystals have been previously reported using bicelle-
detergent matrix [107,110]. I was able, however, to produce standard hex-
agonal bR crystals by modifying the protein purification protocol, increasing 
the protein concentration to about 10 mg/ml (final concentration) and chang-
ing the precipitant to 3.5 M Na2HPO4/NaH2PO4, pH 5.6 (Figure 5.2.3.1.a) For 
comparison, the in cubo conditions were: 2.5–4.5 mg/ml of bR, 0.7–4.0 M 
Na/K-Pi, 1.5–3.75% methylpentanediol, 0.36–0.48% β-OG, at a final pH of 5.6 
[105]. 
 
Nearly complete data sets were collected from wild-type, bR D85N/T121V 
and the carboxyl terminal truncation, TGAI∆229-248. The bR D85N/T121V    
mutant diffracted to at least 2.3 Å resolution on the microfocus beamline 
ID13 at the ESRF (Table 5.2.3.1). This beamline gave substantially improved 
signal-to-noise ratios and resolutions over BW7A at DESY/Hamburg (Table 
5.2.3.1). Both wild-type and bR D85N/T121V have the same unit cell pa-
rameters as crystals obtained in cubo. I found molecular replacement solu-
tions for wild-type and bR D85N/T121V, and refined the bR D85N/T121V 
structure (Table 5.2.3.1). My current models show the same crystal packing 
as seen in the crystals grown in cubo, and, not surprisingly, the twinning is 
as bad [134]. The model of bR D85N/T121V suggests that the D85N breaks 
the network of hydrogen bonds and cause a small change in the middle of the 
transmembrane helix network. The obvious result of this mutation is that a 
proton can no longer be transferred from the Schiff base to residue 85 via 
water 402 (1C3W numbering). The retinal chromophore position and the hep-
tahelical transmembrane alpha helices are in an essentially unaltered confor-
mation when compared to the wild-type bR structure (unpublished). 
 
The bicelle-lipid-detergent method is thus a promising protocol for hepta-
helical transmembrane proteins. These unpublished results also show that 
membrane protein crystallization depends on the crystallization matrix, not 
only the precipitant(s), and so studies of novel crystallization matrices should 
continue. 
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Figure 5.2.3.1: bR and bR-α2b-AR crystals. Crystals (left panel) grown in bi-
celle-detergent matrix with the subsequent 1.0˚ oscillation image (right). (A) 
Wild-type hexagonal bR crystals (50 x 50 x 5 µm) diffracted to 2.8 Å resolu-
tion (dose of 1,500 units, BW7/DESY). (B) Hexagonal crystals of bR double 
mutant (D85N/T121V). The resolution is at 2.25 Å at the edge of the frame 
(4 seconds, ID13/ESRF). (C) Diamond-like crystals of TGAI∆229-248 mutant 
diffracted to 3.5 Å. (D) Wild-type bR P21 crystals. (E) Needle-like crystals of 
TGAII∆238-248 mutant. These crystals diffract to very low resolution (>10 Å) 
at BW7/DESY. (F) Hexagonal-like crystals of bR-α2b-AR 3i (203-292) fusion. 
These crystals diffracted to only very low resolution (only few reflections 
>15 Å; 30 min, home-source). (D and E) the diffraction image is not shown. 
 
Table 5.2.3.1: Summary of the crystallographic data. 
 D85N/T121V TGAI∆229-248 Wild-type TGAI∆229-248 
Beamline ID13/ESRF ID13/ESRF BW7A/DESY BW7A/DESY 
Wavelength 
(Å) 
0.9755 0.9755 0.8453 0.8453 
Expose time 
(s/image) 
4 2 Dose mode 
1,500 units 
(ca. 600 s) 
Dose mode 
4,000 units 
(ca. 1600 s) 
Space group  P63 P21 P63 P21 
Diffraction 
range (Å) 
30.0-2.3 
(2.39-2.30)2 
30.0-3.5 
(3.56-3.5)2 
20.0-2.8 
(2.90-2.80)2 
20.0-4.0 
(4.14-4.00)2 
Unit cell pa-
rameters (Å) 
a=b=58.85, 
c=106.74 
a=105.66, 
b=105.85, 
c=60.98 
α=β=γ=90˚ 
a=b=58.82, 
c=108.16 
a=105.97, 
b=105.49, 
c=61.17 
α=β=γ=90˚ 
Observed   
reflections 
80,151 109,819 114,296 53,801 
Unique      
reflections 
9,318 16,824 5,296 11,827 
Completeness 
(%) 
92.3 (94.3)2 93.9 (96.3)2 79.8 (76.7)2 92.9 (88.5)2 
I/σ 12.6 (2.1)2 15.5 (3.9)2 9.8 (3.2)2 2.9 (1.78)2 
Rmerge1 (%) 8.7 (38.5)2 7.9 (24.3)2 13.6 (39.4)2 16.5 (34.6)2 
Estimation of 
twinning frac-
tion3 
44% - 44% - 
Rwork/Rfree 5% 
(%) of the 
current model 
16.2/24.8  19.6/28.3  
1Rmerge = ΣhklΣi|Ii(hkl)-<I(hkl)>|/ΣhklΣiIi(hkl). 2Outer resolution shell. 
3Estimated using the merohedral crystal twinning server; www.doe-
mbi.ucla.edu/Services/Twinning/ 
 
5.3. G protein coupled receptors show unusual patterns of intrinsic unfolding 
(Study III) 
 
Although I could produce, purify and crystallize the bR-α2b-AR 3i chimera(s), 
the diffraction quality was very poor, while the wild-type bR crystals dif-
fracted to near atomic resolution (Figure 5.2.3.1). Targeted replacement of 
surface residues with large flexible side chains by ones with more rigid side 
chains lead to better quality crystals for x-rays [112,113]. While studying 
this approach further, I noticed that the amino acid sequence and 
charge/hydrophobicity distribution of α2b-AR 3i is very unusual when com-
pared to both “standard” soluble proteins and “standard” integral membrane 
proteins. Analysis of this sequence by several unfolding servers such as Dis-
EMBL [126] and FoldIndex [119,142] (Table 5.3.1; Study III, Figures 3 and 
4) showed that a large portion of α2b-AR 3i is probably intrinsically disor-
dered (Figure 5.3.1 and Table 5.3.1). We therefore decided to undertake a 
database survey and compare sequences of human GPCRs, membrane pro-
teins of known structure (MPSs) with soluble proteins from the protein data 
bank and with previously identified IUPs using the FoldIndex server. 
 
Table 5.3.1: Comparison of the longest predicted disordered regions using 
the DisEMBL and FoldIndex servers. The 20 human GPCRs that contain the 
longest predicted disordered regions are listed. A set of 343 full length     
human GPCRs sequences were analysed. The sequences were unique and 
cross-referenced to the GPCRDB database (http://www.gpcr.org). 
 
Longest predicted disordered region by DisEMBL  Longest predicted disordered region by 
FoldIndex 
Rank Residues Receptor name Subclass Rank Residues Receptor name Subclass 
1 83 α2c adrenocep-
tor 
A 1 109 D2 dopamine 
receptor 
A 
2 75 Extracellular 
calcium-
sensing recep-
tor  
C 2 97 Muscarinic 
acetylcholine 
receptor M4
A 
3 66 Frizzled 8 Frizzled 3 96 Thyrotropin 
receptor 
A 
4 64 Frizzled 6 Frizzled 4 94 Brain-specific 
angiogenesis 
inhibitor 3 
B 
5 58 Neuropeptide 
FF receptor 2 
A 5 91 Histamine H1 
receptor 
A 
6 55 Melatonin-
related recep-
tor 
A 6 90 Muscarinic 
acetylcholine 
receptor M2
A 
7 53 Prostaglandin 
E2 receptor, 
A 7 86 Cadherin EGF 
LAG GPCR 1 
B 
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EP1 subtype 
8 53 α2a adrenocep-
tor 
A 8 85 Frizzled 8 Frizzled 
9 52 α2b adrenocep-
tor 
A 9 84 γ-aminobutyric 
acid type B 
receptor, sub-
unit 1 
C 
10 50 Somatostatin 
receptor type 1 
A 10 84 Extracellular 
calcium-
sensing recep-
tor  
C 
11 49 Metabotropic 
glutamate re-
ceptor 5 
C 11 83 Somatostatin 
receptor type 
3 
A 
12 46 Cadherin, EGF 
LAG GPCR 2 
B 12 82 Muscarinic 
acetylcholine 
receptor M3
A 
13 45 Frizzled 3 Frizzled 13 82 Cadherin EGF 
LAG GPCR 3 
B 
14 45 Histamine H3 
receptor 
A 14 78 Muscarinic 
acetylcholine 
receptor M1
A 
15 45 Tachykinin  
receptor 1 
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Figure 5.3.1: Folding prediction plots of human and Danio rerio (zebrafish) 
α2b-AR. Produced using FoldIndex and DisEMBL. A window of 25 residues 
was used. Although the 3i domain displays great amino acid variation, in both 
cases large portions of 3is are predicted as unfolded regions. The unfolded-
ness of 3i has been preserved during evolution. 
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As expected, the Foldindex values were the same for full-length sequences 
of MPSs and human GPCRs (Study III, Table 1), indicating that the proteins 
are folded overall. I also classified the MPSs according to the UC Irvine sys-
tem (http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html). The distri-
bution of the longest disordered region of human GPCRs and MPSs were dif-
ferent; human GPCRs contain many long regions with predicted disorder, 
whereas membrane proteins of known three-dimensional structure, particu-
larly heptahelical transmembrane proteins, do not have such regions. The 
FoldIndex server plots indicated that the predicted disorder was mainly in 
the extramembranous part of GPCRs. For this reason, the folding of human 
GPCR extramembranous domains was predicted using the FoldIndex server. 
As in α2b-AR 3i, the amino region (55% of the human GPCRs studied), the 
carboxyl region (69% of the human GPCR studies) and the 3i domain (56% of 
the human GPCRs studied) included large regions predicted to be natively 
unfolded. The 1i, 1e and 3e regions appeared to be less unfolded (Study III, 
Table 2). 
 
I selected the human rhodopsin-like GPCRs (family A) for further comparison 
as the rhodopsin-like GPCRs members contained the longest predicted dis-
ordered regions (Tables 5.3.1.; Study III, Table 1), and as my target protein, 
α2b-AR, is a member of this subfamily. The human rhodopsin-like GPCRs, 
MPSs and folded proteins have similar overall mean net charge, mean net 
hydrophobicity and Foldindex (Study III, Table 1). The long (mean length of 
52 residues) rhodopsin-like GPCR 3is were clearly predicted as unfolded 
(Foldindex score of -0.145; Study III, Table 1). The amino termini of human 
rhodopsin-like GPCRs were predicted as marginally folded (FoldIndex score 
of 0.07; mean length 50 residues; Study III, Table 1) and the carboxyl termini 
marginally unfolded (score of -0.003; mean length 57 residues). The pre-
dicted unfolding is probably because the 3i have very high mean net charge 
(0.17), which is higher than ordinary IUPs (0.12). The amino and carboxyl 
termini (0.05 and 0.06) have slightly higher mean net charges than soluble 
folded proteins (0.04; Study III, Table 1). The amino and carboxyl termini of 
rhodopsin-like GPCRs are thus probably more ordered than 3i. 
 
Full-length IUPs have atypical amino acid distributions, they are enriched in 
Gln, Glu, Lys, Pro and Ser, but depleted in Asn, Cys, Ile, Leu, Met, Phe, Trp 
and Tyr [120]. Glu and Lys are mainly responsible for the uncompensated 
charged groups that lead to large net charge and low mean hydrophobicity at 
physiological pH. For this reason, the amino acid distribution of human 
rhodopsin-like GPCRs, their 3i domains and the amino and carboxyl termini 
were compared with those of MPSs and IUPs. Interestingly, the amino acid 
distribution in 3i loops was considerably different from all other datasets 
mentioned above (Table 5.3.2). Human rhodopsin-like GPCR 3i are very 
positively charged because the percentage of Arg residues is very high 
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(13.9%). Some of this can be explained by the “positive in” rule: i.e. Arg and 
Lys are used for positioning the transmembrane helices at the lipid bilayer 
[143]. The percentage is three times than in IUPs, MPs and globular pro-
teins. The carboxyl termini of GPCRs are also positively charged, but not the 
amino termini of GPCRs. 
 
There are also other differences between IUPs and human rhodopsin-like 
GPCR 3i (Table 5.3.2). The 3i have high percentages of Ala and Leu and also 
slightly higher percentage of Cys, His and Trp, while Asp and Glu are       
depleted (Table 5.3.2). The intracellularly located carboxyl termini are rather 
similar to the 3i domains. The extracellularly located amino termini are dif-
ferent than 3i: the percentage of Asp and Glu is not low, whereas Lys, His 
and Arg are. The membrane proteins of solved structure do not have simi-
larly increased Arg and Lys. Consequently, these properties of the human 
rhodopsin-like GPCR 3i serve presumably other functions. 
 
Table 5.3.2: Comparison of amino acid residue distribution of ordered and 
disordered proteins. 
Amino 
acida
Globularb MPsb GPCRsd 3id Nd Cd IUPb
Ala 8.15 8.56 8.45 9.17 8.31 6.96 7.15 
Asn 4.66 3.85 3.82 2.98 6.50 3.74 2.06 
Asp 5.78 4.47 2.92 2.21 4.92 4.22 5.05 
Arg 4.61 4.56 5.27 13.89 3.58 8.94 4.21 
Cys 1.64 1.14 3.24 1.67 1.85 3.76 0.61 
Gln 3.69 3.36 2.58 4.80 3.53 4.28 4.46 
Glu 5.98 4.90 3.12 4.52 6.28 5.31 14.26 
Gly 7.99 8.48 5.36 5.53 7.98 5.60 4.31 
His 2.33 1.95 2.04 2.61 1.88 2.70 1.15 
Ile 5.43 5.78 6.26 4.65 3.23 3.00 3.67 
Leu 8.37 10.13 12.47 8.05 9.35 8.42 5.44 
Lys 5.43 4.16 3.53 10.26 2.70 6.14 10.43 
Met 2.03 2.66 2.62 2.21 2.73 1.50 1.30 
Phe 3.95 4.96 5.71 1.94 3.17 4.52 1.66 
Pro 4.61 4.63 5.18 4.20 8.25 6.26 12.07 
Ser 6.31 6.23 7.96 7.78 10.79 11.71 6.91 
Thr 6.15 5.76 6.05 5.61 6.48 5.55 5.14 
Trp 1.55 2.03 1.92 1.07 1.58 0.77 0.32 
Tyr 3.64 3.53 3.51 1.76 2.59 0.83 1.42 
Val 7.00 7.15 8.06 5.53 4.30 4.48 8.02 
Xe  1.72      
Bold are significantly enriched and italic depleted when IUPs are compared 
with folded proteins in the PDB. Dark and light blue are for increases 
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>3%/>x3 and >1.5%/>2, respectively, when compared to globular proteins. 
Dark and light red are for decreases for <3%/<x3 and <1.5%/<2, respec-
tively, when compared to globular proteins. The table is modified from paper 
III. 
aAmino acid frequencies are in %. 
bData from [120]. 
cData from reference set of membrane proteins (n=91). 
dData from human rhodopsin-like GPCRs (n=147). 
eSide chains were not defined in the PDB entries. 
 
The results from study III suggest that rhodopsin-like GPCRs extramembra-
nous domains include large regions of disorder. The extracellular aminoter-
minal domains appears to be marginally ordered, while the intracellular 3i 
and carboxyl termini domains are probably unfolded at physiological pH. The 
rhodopsin-like GPCR 3i have a unique amino acid distribution which differs 
from IUPs, membrane proteins of solved structure and folded proteins. All 
IUPs and IUP like regions may thus share low net hydrophobicity and high 
net charge. These properties have been conserved during evolution, but the 
amino acid distribution has not. These results also emphasize the importance 
of a selection process of suitable GPCR or modifications of GPCR sequences 
for structural analysis as IUPs are unlikely crystallize. 
 
5.4. Role of third intracellular loop of α2b-AR on ligand binding and G protein 
activation (Studies III and IV) 
 
In paper IV we investigated the effect of the third intracellular loop of α2b-AR 
on ligand binding and G protein activation by using 3i truncations, a variety of 
tightly/weakly binding antagonists and agonists and synthetic peptides. Vari-
ous deletion variants were constructed: deletion of the entire 3i loop (1∆: 
∆195-359), deletion of the N-terminal region of 3i (4∆: ∆206-348), mid-3i 
loop deletion (3∆: ∆245-348), C-terminal 3i loop deletion (5∆: ∆245-359), 
and a combination of 4∆ and 5∆ (6∆: ∆206-359). As can be seen, the dele-
tions overlap (Study IV, Figure 1). The 3i deletion constructs were cloned 
into an episomal mammalian vector (pREP4) and produced in CHO-K1 cells 
for functional studies. 
 
Expression of the receptor variants. The 1∆ receptor variant showed neither 
positive immunostaining nor binding to high affinity antagonists ([ethyl-
3H]RS79948-197 or [methyl-3H]rauwolscine). Either the receptor density 
was too low for these assays, or the 1∆ receptor variant can not bind α2b-AR 
radioligands. These results suggest that the 1∆ truncation was not tolerated 
and the 1∆ receptor variant was not folded correctly. The other variants, 
wild-type, 3∆, 4∆, 5∆ and 6∆, were tolerated, based on ligand binding and 
immunostaining results. The expression of the 3∆ variant was low, probably 
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less than the detection limit for the functional [35S]GTPγS assay. We there-
fore decided to focus our main attention on comparison of the three trun-
cated receptor variants, 4∆, 5∆ and 6∆, to wild-type receptor. 
 
In saturation binding assays, the receptor affinities for the high-affinity     
antagonist radioligand [ethyl-3H]RS79948-197 were the same for the recep-
tor truncations and the wild-type receptor, except for the 6∆ receptor vari-
ant, which bound somewhat more weakly (Study IV, Table 1). These results 
suggest that deleting 3i domain residues between Gly206 and Arg359 had no 
effect on antagonist binding, and consequently on effect on the overall fold-
ing of α2b-AR. 
 
Antagonist and agonist binding. In an inhibition binding assay of [ethyl-
3H]RS79948-197 with a set of four different antagonists (rauwolscine, 
RX821002, chlorpromazine and ARC239) and four different agonists ((L)-
norepinephrine, dexmedetomidine, clonidine and UK14,304), the antagonist 
binding was not significantly perturbed by the 3i truncations (Study IV, Table 
2). There was a small change in agonist binding (Study IV, Table 3); clonidine 
and UK14,304 bind the 5∆ receptor variant and wild-type receptors with 
similar binding affinities, but bind the 4∆ and 6∆ receptor variants weaker. 
The difference between the 5∆ and 4∆/6∆ receptor variants is the deletion of 
residues 206-245 in 4∆/6∆. Evidently, this region is involved in wild-type 
receptor interactions with UK14,304 and clonidine. (L)-norepinephrine binds 
the 4∆, 5∆ and 6∆ receptor variants weaker than wild-type. These different 
binding affinities between the 3i truncation variants and wild-type receptor 
might indicate that agonist stabilized conformations can be different for each 
agonist. 
 
Functional [35S]GTPγS assay. In the [35S]GTPγS assay, all the tested receptor 
variants were strongly stimulated by agonist, indicating that Gi/Go protein 
coupling was not significantly perturbed by the 3i truncations. This indicates 
that the main determinants α2b-AR G protein activation are not located be-
tween residues 206 and 359 (Study IV, Table 4 and Figure 2). To further lo-
cate the α2b-AR determinants responsible for activation of G protein, oli-
gopeptides analogous to the extreme amino and carboxyl terminal ends of 
α2b-AR 3i were added to the [35S]GTPγS assay, both with and without ago-
nist stimulation. The oligopeptide corresponding to the carboxyl terminal end 
of α2b-AR 3i, 360RAHVTREKRFTFV372, strongly enhanced [35S]GTPγS bind-
ing. The oligopeptide corresponding to the amino terminal end of 3i, 
195IYLIAKRSNRR205, had no result on basal [35S]GTPγS binding of wild-type, 
4∆ and 5∆ (Figure 5.4.1). 
 
Finally, the Gi/o protein activator region of α2b-AR is fairly buried in the 
membrane bilayer (Stydy IV, Figure 4). The energy minimized model is based 
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on the bovine rhodopsin structure in the inactive form. It could be speculated 
that either only half of the region is needed for the activation interactions 
with G proteins or that TM helix VI moves somehow to the cytosolic side af-
ter agonist binding. There is evidence from spectroscopic studies on other 
family A members that the cytosolic end of TM helix IV moves [20,22]. Most 
probably similar movements happen in the activation of α2b-AR. 
 
The data from paper IV suggest that the regions between 206 and 359 are 
not required for wild-type-like antagonist binding and Gi/Go protein activa-
tion of α2b-AR. Therefore, it is possible to remove these structurally     dis-
ordered regions (Study III), while retaining the functionality of the α2b-AR. 
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Figure 5.4.1: Results of oligopeptide corresponding to the amino terminal end 
(195IYLIAKRSNRR205) and carboxyl terminal end (360RAHVTREKRFTFV372) of 
α2b-AR 3i on [35S]GTPγS binding. Panel A, wild-type receptors; panel B, 4∆ 
receptors; panel C, 5∆ receptors with and without activation with (L)-nor-
epinephrine. Means±S.E.M. Results significantly different between the indi-
cated data-sets, P< 0.05. The figure is adapted from paper IV. 
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5.5. General discussion and future directions 
 
Below I will discuss the implications of my studies for functional and struc-
tural studies of GPCRs and other membrane proteins and propose some fu-
ture directions. 
 
5.5.1. Cellular signalling of GPCRs 
 
GPCRs are key molecules in cellular signalling processes. In addition to in-
teractions with ligands and G proteins, GPCRs associate with several other 
molecules, such as β-arrestins, spinophilin and GPCR kinases. These regu-
late the signalling cascade and subcellular location of GPCRs [27,28,63,64]. 
The structural origins of these interactions are not known: are they based on 
three-dimensional or on linear (IUP) interactions? It is interesting, however, 
that several such proteins interact with the carboxyl terminus and/or 3i 
[63,64]. Our prediction analyses suggest that these regions are mainly un-
folded in vitro (Study III), but presumably fold upon forming a protein com-
plex. For instance, 14-3-3-ζ protein, which interacts with the 3i of α2-ARs, 
can induce conformational changes in target proteins [144]. G proteins inter-
act with 2i, 3i and C terminal regions of GPCRs [10,17]. Our data suggest 
that 2i domains are more structured than 3i and C terminal regions. There-
fore, it would seem that the G protein interactions with GPCRs could require 
three-dimensional structure as well as linear sequence recognition. 
 
It is not surprising that the amino, carboxyl terminal and 3i GPCR extramem-
branous domains are predicted as unfolded. Of the hundreds of IUPs and IUP 
regions identified so far (www.disprot.org/; [118]), the majority act in      
essential biological processes, including regulatory roles in transcription, 
translation, signal transduction and cell cycle control [117,120]. Interest-
ingly, many CNS-located human GPCRs include large regions predicted to be 
disordered (Table 5.3.1. and Study III, Table 1). The intrinsically unfolded 
protein regions of GPCRs seemingly have functional significance. Other in-
teractions and interacting partners may therefore remain to be discovered. 
An IUP may be a convenient way to make possible more interactions with 
other proteins. 
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5.5.2. Target selection and modification of GPCRs and other membrane      
proteins for structural studies 
 
Recombinant GPCRs can be expressed and isolated in near native form from 
several different systems (Tables 2.2.2.1 and 5.2.1). These systems provide 
a large spectrum of hosts for functional and biochemical studies in vivo and 
in vitro. However, it should be noted that the functional and correctly local-
ized GPCR depends ultimately upon cell type, secondary messenger system 
and receptor population in vivo. These might influence functional studies, and 
consequently should be thoughtout when the expression system is selected 
for functional studies. 
 
Structural studies require large amounts of fully homogenous receptor. Based 
on this and our previous studies [88,96], the following factors should be 
considered when GPCR are selected for structural studies: a) the native 
source and functions of GPCR in vivo (such as subcellular localisation, activ-
ity and expression level), b) sequence properties (such as the flexibility, 
need for post-translational modifications and size), c) existence of purifica-
tion protocol, activity measurement and refolding methods, d) stability and 
heterogeneity of GPCR and e) cost of the over-expression and purification 
procedures (especially scale-up process, cost of stabilizing ligands and de-
tergents). In the light of the current work, I will emphasize some technically 
and methodologically important points. 
 
The selection of host system. Several hosts should be tested, preferably in 
parallel. The costs of mammalian systems are usually vast when compared to 
lower organisms (Table 5.5.2.1). Usually 1 mg of pure receptor is required 
for starting two-dimensional crystallization trials, while 10 mg is required for 
starting three-dimensional crystallization trials. For instance, the structure 
determination of LacY required over 1 g of purified membrane protein [145]. 
This implies that the initial expression levels have to be high and scale-up 
has to be relatively easy and inexpensive (Table 5.5.2.1). No current GPCR 
expression system meets these criteria. Based on the work reported here, 
the lower limit of expression for purification and crystallization is much more 
than 0.5 nmol/mg of membrane protein – i.e. much more than 1 mg/l of culti-
vation. Most viral systems saturate the cellular transmembrane machinery 
and inhibit host cell protein synthesis. This can cause immature forms of 
over-expressed GPCR, and therefore a heterogeneous pool of specimens. 
For instance, both in Semliki Forest virus and baculo-infected host cells 
([96,146] and unpublished results), the the α2b-AR-eGFP was almost exclu-
sively located in cis-trans-Golgi and other intracellular membrane compart-
ments, not in the plasma membrane. The stable expression systems, such as 
yeasts, were better [87,88]. The yields of the full length α2b-AR tested in H. 
salinarum were not sufficient for isolation (Study I and 5.5.2.1). Codon opti-
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mization for full length α2b-AR should be tested, since the fusion protein ap-
proach produced quite well (Study II, Table 2). 
 
Table 5.5.2.1: Comparison of expression and purification of α2b-AR yield    
using various over-expression hosts. 
Host 
 
 Receptor 
density
Production 
level 
Cost 
> 
Crystallization 
set-up/l#
Reference
 pmol/mg µg/l €/l No of wells    
E. coli Insoluble 1000 5 - [81], un-
published 
H. salina-
rum 
Trace (in-
tact) 
 
 5 - Study I 
 1800 (bR-
α2b-AR 3i 
fusion) 
2000-9700 5 > 100 Study II 
S. cere-
visiae 
10-40 100-400 20 5-10 [87,88] 
P. pastoris 2-10 20-100 40 <5 Unpublished 
Baculo-
insect cells 
20-100 400-600 100 10-20 [140] 
CHO/semi-
stable 
5-25 <100 500 - Study IV 
CHO/SFV 100-200 500-1000 1000 10-20 [96] 
#Estimated that 1 µl of protein (10 mg/ml)/well, and overall purification yield 
of 20%; only reagent and other material costs are estimated. 
 
In silico analysis of the target. Comprehensive in silico analysis should be 
done to increase the success rate of structure determination. For instance, it 
is unlikely that IUP or IUP-like domains will crystallize. Only 1% of the 
structures in the PDB [72] contain disordered regions longer than 40 resi-
dues [126,147]. When considering prokaryotic host systems, GPCRs lacking 
post-translational modifications should be preferred, as done here. GPCRs 
carrying large extramembranous domains may cause stability, aggregation 
and degradation problems, as seen for α2b-AR ([96,146], and unpublished), 
and therefore, are not optimal. 
 
Using homologous or analogous proteins for crystallization has often been a 
very effective approach [103,148]. Unfortunately, there are no prokaryotic 
GPCRs. Nonetheless, the usefulness of extremophiles as a host, as described 
herein, could be considered. 
 
Genetic modification. Modification of the target protein by recombinant tech-
niques has been successful for soluble proteins and recently for membrane 
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proteins too [112,113]. When successful, it usually works by increasing sta-
bility, decreasing structural heterogeneity and/or increasing crystal packing 
contacts. This can be also achieved, for instance, by use of antibody frag-
ments [103,116] or other co-proteins/ligands. 
 
The number of constructions should be maximized. A variety of different   
detection and purification tags and expression vectors should be tested in all 
expression hosts such as 6-12xHis, Flag peptide, GST, maltose-binding pro-
tein and eGFP. If possible, tags should be cleavable before crystallization. In 
our hands, the eGFP tags have been useful both for rapid detection of       
expressible constructs and sub-cellular localizations of GPCR ([96,146], 
study II and unpublished). Possibly, eGFP could also be useful for detect 
crystals from in cubo and BLD matrixes. The cloning step, if possible, should 
be automatic or semi-automatic by using GatewayTM or comparable systems. 
In this study, the numbers of constructs for α2b-ARs were 30, 24 and 7 
(Studies I, II and III, respectively); these were done the traditional way. 
These numbers are good starting points, but still far too low to obtain a 
proper picture of the advantages and disadvantages of the H. salinarum sys-
tem. 
 
Solubilization and crystallization. The selection of proper detergent(s) is im-
portant not only for the stability and activity of GPCRs, but also for crystalli-
zation. It is advisable to test several detergents and detergent mixtures; 
there are detergents screens that are useful in this process.  
 
Many structural genomics projects use an initial crystallization panel of 500 
or more conditions from commercial suppliers [149]. If initial conditions are 
not found, the protein construct is either abandoned or genetically modified. 
With combinations of different detergents, this complicates the crystallization 
screening of membrane proteins. More than 100 initial conditions were tested 
for the bR-α2b-AR 3i (203-292) using different detergents (Study II and un-
published). 
 
Data collection. Membrane protein crystals require use of synchrotron radia-
tion sources for obtaining good quality diffraction. Consequently, frequent 
access to a high energy x-ray source should be arranged. In this work, the 
initial hexagonal crystal obtained from the bR-α2b-AR 3i (203-292) con-
struct, was unfortunately analysed only on our in-house source. The crystals 
from the optimized conditions will be analysed at the European Synchrotron 
Radiation Facility (ESRF). It is worth mentioning that the D85N/T121V mu-
tant of bR hardly diffracted on our home source, but crystals diffracted to 4 
Å at BW7/DORIS, Hamburg and to 1.8 Å at ID13/ESRF ring (Table 5.2.3.1, 
Figure 5.2.3.1 and unpublished). 
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5.5.3. Summary and future directions 
 
To summarize, it was not surprising - although disappointing - that the ulti-
mate goal of solving the crystal structures of an α2 adrenoceptor was not 
achieved. The only GPCR for which a crystal structure has been solved is 
bovine rhodopsin [4]. In addition, an extracellular ligand binding domain of 
the metabotrobic glutamate receptor and an extracellular follicle-stimulating 
hormone binding domain have been solved [150,151]. This work and our 
original communications may provide useful alternative approaches to obtain 
structural information about GPCRs, and suggest new functional and struc-
tural features of extramembranous parts of GPCR family A members. 
 
The current study should have an impact on the development of new methods 
to study GPCRs. The difficulties of studying structure and function in these 
proteins are well known. Our original articles show that it is possible to pro-
duce a fusion containing a large segment of the α2b adrenoceptor. Our pre-
liminary crystallization results are quite promising, and it can be hoped that 
co-crystallising with G protein or other co-proteins, refining the crystalliza-
tion conditions, and using the synchrotron will allow a structure to emerge. 
 
The determination of the 3i loop structure in the context of the bR fusion 
would be significant progress and lay the groundwork for more elaborate 
studies, perhaps involving the substitution of multiple loops from GPCRs into 
the bR scaffold. 
 
Secondly, the current study suggests that the GPCR 3i domains appear to be 
examples of intrinsically unstructured protein regions. From a structural 
point of view, there are three obvious ways to overcome this problem. 
Firstly, one could identify and abandon all target proteins that carry disor-
dered regions. This will cause the problem that structural studies of key-
signalling proteins such as GPCRs and other important proteins for cellular 
signalling would not be possible [117,120]. The second way is to remove, if 
possible, the intrinsically unstructurated protein regions [126], as we have 
done here for α2b-AR, without affecting the functionality of the receptor. The 
third way is co-crystallization of GPCR with a proper partner that will order 
the structure of the disordered region. This is most probably required for 
successful crystallization of our bR-α2b-AR 3i fusion protein.  
 
Finally, to close with a wider perspective: 50 years have passed since the 
myoglobin structure was solved by John Kendrew and co-workers [152] – 
followed by more than 30,000 soluble protein structures. More than 30 years 
have elapsed since the first membrane protein structure was solved [153] 
using electron microscopy – followed by less than 200 hundred membrane 
protein structures. The in cubo crystallization method was published nearly 
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ten years ago [105]; a detailed structural analysis of bacteriorhodopsin’s 
photocycle followed rapidly. Now four years have passed since the report 
describing the first, and still the only, crystal structure of a GPCR [4]. The 
success rate is not huge; it is hard to believe that the other nearly one thou-
sand GPCRs will be solved in the near future using the current spectrum of 
methodologies. Alternative methods and ideas have to be explored, some of 
which are described here. 
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6. 
 
Conclusions 
 
he following conclusions may be suggested on the basis of the pre-
sent study: 
 
 
T
(1.) H. salinarum can be used as a high-level production host for G protein 
coupled receptor extra-membranous domains as fusion protein with bacteri-
orhodopsin. 
 
(2.) Expression of nearly full-length α2b-AR in the H. salinarum host system 
was detectable both at mRNA and protein levels, but the protein levels were 
low and unstable. There are several possible explanations for this: different 
codon usage of H. salinarum, different membrane environment and membrane 
folding machinery of H. salinarum, lack of G proteins in H. salinarum or 
modifications at the amino and/or carboxyl termini of the receptor fusions. 
Further optimization is thus necessary for high level production of functional 
intact adrenoceptor in the H. salinarum host system. 
 
(3.) Human G protein coupled receptors contain structural flexibility that is 
not found in membrane proteins whose x-ray structures have been solved. 
 
(4.) Database analysis indicates that there is not a single type of intrinsically 
unfolded protein or intrinsically unfolded protein regions. 
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